

EXHIBIT A

CURRICULUM VITAE AND BIBLIOGRAPHY

William S. Dalton, Ph.D., M.D.
Chief Executive Officer & Center Director

ADDRESS: H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive
Tampa, FL 33612-9497
(813) 615-4261
FAX: (813) 615-4258
dalton@moffitt.usf.edu

Home: 15350 Amberly Drive #4821
Tampa, FL 33647

EDUCATION:

1971 University of New Mexico, Albuquerque, NM (B.A. -- Chemistry and Philosophy)
1976 Indiana University, Indianapolis, IN (Ph.D. -- Toxicology/Medical Life Sciences)
1980 Indiana University, Indianapolis, IN (M.D.)
1980-81 Medicine Internship, Indiana University, Indianapolis, IN
1981-83 Medicine Residency, University of Arizona, Tucson, AZ
1983-85 Oncology Fellowship, University of Arizona, Tucson, AZ
1983-85 Clinical Pharmacology Fellowship, University of Arizona, Tucson, AZ
1994 Visiting Scientist (Sabbatical), Department of Biochemistry (Dr. Philippe Gros), McGill University, Montreal, Quebec, Canada

PROFESSIONAL AND HONORARY SOCIETIES:

- Phi Sigma Tau, National Honor Society in Philosophy
- Sigma XI, Scientific Research Society
- Alpha Omega Alpha, National Honor Society of Medicine
- American Society of Hematology
- American Society of Clinical Oncology
- American Association of Cancer Research
- American Society for Blood and Marrow Transplantation

ACADEMIC HONORS:

1980 K.K. Chen Award in Pharmacology, Indiana University
1985 Faculty Career Development Award in Clinical Pharmacology,
Pharmaceutical Manufacturers Association Foundation
1985 New Investigator Research Award, National Cancer Institute

- 1991 Raymond R. Paradise Memorial Lecturer, Department of Pharmacology, Indiana University
- 1993 10th Annual Theodore Segal Memorial Lecturer, Department of Medicine, University of Louisville
- 1993 The Golden Apple Teaching Award, Internal Medicine Housestaff Award, University of Arizona
- 1993-2000 Best Doctors in America
- 1995 University of North Carolina/Glaxo Visiting Professor Award in Clinical Pharmacology
- 2002 Fellowship in the American College of Physicians-American Society of Internal Medicine
- 2003 Best Doctors for 2003, *Tampa Bay Metro* magazine, August/September edition

BOARD CERTIFICATION:

Internal Medicine (September, 1983)
Medical Oncology (November, 1985)

ACADEMIC APPOINTMENTS:

- 1976-1981 Research Associate, Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN
- 1985-1989 Assistant Professor of Internal Medicine, Section of Hematology and Oncology, University of Arizona College of Medicine, Tucson, AZ
- 1986-1996 Adjunct Assistant Professor of Pharmacology & Toxicology, University of Arizona College of Medicine and Pharmacy, Tucson, AZ
- 1989-1993 Associate Professor of Medicine (tenured), Section of Hematology and Oncology, University of Arizona College of Medicine, Tucson, AZ
- 1988-1996 Director of Bone Marrow Transplant Program, Section of Hematology and Oncology, University of Arizona College of Medicine, Tucson, AZ (Founding Director)
- 1993-1996 Professor of Medicine (tenured), Section of Hematology and Oncology, University of Arizona College of Medicine, Tucson, AZ
- 1996 Deputy Director, Arizona Cancer Center, University of Arizona, Tucson, Arizona
- 1997-2001 Associate Center Director for Clinical Investigations, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL
- 1997-2001 Professor of Medicine, Department of Internal Medicine, University of South Florida, Tampa, FL
- 1997-2001 Professor of Pharmacology and Therapeutics, Department of Pharmacology and Therapeutics, University of South Florida, Tampa, FL
- 1997-2001 Professor of Biochemistry and Molecular Biology, Department of Biochemistry and Molecular Biology, University of South Florida, Tampa, FL
- 1999-2001 Deputy Director, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL
- 1999-2001 Professor and Founding Chairman, Department of Interdisciplinary Oncology (Interdisciplinary Oncology Program), University of South Florida, Tampa, FL

2000-2001 Associate Vice-President of Health Sciences, University of South Florida, Tampa, FL

2001-2002 Dean, College of Medicine, University of Arizona, Tucson, AZ

2001-2002 Professor, Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ

2002-pres. Chief Executive Officer and Center Director, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL

SERVICE:

Intramural: University of Arizona:

- 1) College of Medicine, Graduate Education Advisory Committee, 1987-1996
- 2) College of Medicine, Department of Medicine House Staff Committee, 1985-1994
- 3) University Medical Center, Univ. Hospital Med. Staff Executive Comm., member at large, 1990-1993
- 4) College of Medicine, Human Subjects Committee, Institutional Review Board, 1990-1994
- 5) College of Medicine, Institutional Grant Review Committee, American Cancer Society, 1987-1996
- 6) Junior Faculty Advisor, Department of Medicine, 1995-1996
- 7) UMC Medical Staff Hearing Committee, University Medical Center, 1995-1996
- 8) Cancer Biology Interdisciplinary Program, 2002

University of South Florida and the H. Lee Moffitt Cancer Center and Research Institute:

- 1) Moffitt Cancer Center, Executive Council, 1997-2001
- 2) Moffitt Cancer Center, Scientific Leadership Council, 1997-2001
- 3) Moffitt Cancer Center, Business Leadership Council, 1999-2001
- 4) Moffitt Cancer Center, Clinical Leadership Council, 1999-2001
- 5) Moffitt Cancer Center, Institutional Grant Review Committee, American Cancer Society, 1997-2001
- 6) College of Medicine, Department of Medicine, Molecular Medicine Committee, 1997-1999
- 7) College of Medicine, Green and Gold Committee, Advisory Comm. On Research, 1998-1999
- 8) College of Medicine, Committee on Governance, 1999
- 9) College of Medicine, Committee on Physician Compensation and Incentive Plan, 1999
- 10) College of Medicine, Search Committee for Assoc. Dean for Research, 1999
- 11) College of Medicine, Dean's Executive Council, 1999-2001
- 12) College of Medicine, University of South Florida Practice Group, Board of Governors, 1999-2001
- 13) University of South Florida, Intellectual Property Advisory Committee, 1999-2001
- 14) University of South Florida, Search Advisory Committee for USF President, 1999
- 15) University of South Florida, Search Committee for Vice President of Research, 2001

Extramural:

- 1) National Institute of Health/National Cancer Institute
 - a) Ad Hoc Reviewer Experimental Therapeutics -2, Study Section, NIH/NCI, 1992
 - b) Permanent Reviewer Experimental Therapeutics-2, Study Section NIH/NCI, 1993-1997
 - c) Chairman, Experimental Therapeutics-2, Study Section NIH/NCI, 1995-1997
 - d) Ad Hoc Reviewer Subcommittee-H, Study Section, NIH/NCI, 1998
 - e) Reviewer, Terry Fox Cancer Foundation, NCI, Canada, 1999-present
 - f) Permanent Reviewer, Subcommittee-H, Study Section, NIH/NCI, 1999-2000
 - g) Ad Hoc Reviewer for NCI P01 Grants, 1990, 1993, 2000
 - h) NCI Progress Review Group in Leukemia, Lymphoma and Myeloma, 2000-2001
- 2) American Association of Cancer Research
 - a) Clinical Investigations Committee, 1993-1994
 - b) Program Committee member, 1995-present
 - c) Chairman, Pharmacology/Therapeutics Subcommittee, Program Committee, 1996, 1999
 - d) Rosenthal Award Nomination Committee, 1996, 1999; Chair 2002
 - e) Membership Committee, Chairman, 1998

- f) Education Committee, 1997-1998
 - g) Exhibits Committee, 1999-2000
 - h) Clinical Cancer Research Committee, 2000-2004
 - i) Scientific Advisory Board for NCI/EORTC/AACR New Molecular Targets Meeting, 2000, 2001
- 3) American Society of Hematology
- a) Program Committee, Molecular Pharmacology/Drug Resistance Committee 1996-1999
 - b) Program Committee and Chairman Molecular Pharmacology/Drug Resistance Subcommittee, 1997
 - c) Program Committee, CLL/Myeloma, Biology & Clinical Investigations, 1998
 - d) Program Committee and Chairman, CLL/Myeloma, Biology & Clinical Investigations, 1999, 2002
 - e) Education Committee, Organizer for Myeloma Educational presentations, 2001
- 4) American Society of Clinical Oncology
- a) Education Committee Member, 1989-1993
 - b) Chairman, Education Committee, 1992-1993
- 5) Eastern Cooperative Oncology Group
- a) Working Committee in Myeloma, 1997-present
- 6) Southwest Oncology Group Working Committees, 1985-1996
- a) Breast Cancer
 - b) Myeloma
- 7) Association of American Cancer Institutes
- a) Member, Board of Directors, 2003-present
- 8) Scientific Advisory Boards
- a) Member, External Scientific Advisory Board, University of Illinois Cancer Center, 1998-1999
 - b) Member, External Scientific Advisory Board, University of California, Irvine Cancer Center, 1998-2002
 - c) Member, Scientific Advisory Board, Kathy Giusti Multiple Myeloma Research Foundation, 1998-present
 - d) Member, Scientific Advisory Board, Novation Pharmaceuticals, 1999-present
 - e) Reviewer, Doris Duke Foundation for grants in cancer research, 2000-present
 - f) Member, External Scientific Advisory Board, University of Tennessee College of Medicine, 2003-present
 - g) Member, External Scientific Advisory Board, University of New Mexico Cancer Center, 2003-present
 - h) Member, External Scientific Advisory Board, Purdue Cancer Center, Purdue University, 2003-present

Community: 1) Trustee, Board of Directors, Tampa Preparatory School, 1998-2001
2) Board Member, Greater Tampa Chamber of Commerce, 2003-present

EDITORIAL RESPONSIBILITIES:

1. Associate Editor, Archives of Internal Medicine, 1988-1996
2. Editorial Advisory Board, Archives of Internal Medicine, 1997-present
3. Editorial Advisory Board of Clinical Cancer Research, 1993-2002
4. Editorial Advisory Board of International Journal of Oncology, 1996-present
5. Editorial Advisory Board of Cancer Therapeutics, 1998-1999
6. Editorial Advisory Board of Critical Reviews in Oncology/Hematology, 1999
7. Editorial Board for Leukemia, 2001-present
8. Section Editor for Current Opinions in Oncology, Experimental Therapeutics, 1998-present
9. Editorial Board for Molecular Cancer Therapeutics, 2001-present
10. Editorial Board for American Journal of Oncology Review, 2002-present

11. Editorial Board for Investigational New Drugs, 2002-present
12. Editorial Board for Anti-Cancer Drugs, 2002-present
13. Reviewer of manuscripts for the following journals:
 - Biochemistry
 - Biochemical Pharmacology
 - Blood
 - British Journal of Cancer
 - Cancer Research
 - Cancer Chemotherapy and Pharmacology
 - Clinical Pharmacology and Therapeutics
 - International Journal of Cancer
 - Journal of Cellular Biochemistry
 - Journal of Clinical Oncology
 - Journal National Cancer Institute
 - Life Sciences
 - New England Journal of Medicine
 - Proc. National Academy of Sciences

PAST FUNDING:

- 1) Career Development Award. Pharmaceutical Manufacturers Foundation, 1985-1988, \$90,000. (100%).
- 2) Principal Investigator, NCI First Award R29-43043, Drug Resistance in Multiple Myeloma, 1986-1991, \$350,000. (50%).
- 3) Principal Investigator, Knoll Pharmaceutical Co., "R-Verapamil as a Reversing Agent in Drug-Resistant Cancer," 1990-1992, \$77,460.
- 4) Project Leader, NCI grant P01-CA-17094-16, "Drug Resistance in Breast Cancer", 1988-1992, \$442,478
- 5) Principal Investigator, Immunex R&D Corp., "Phase III Study of Recombinant Human GM-CSF Following Allogeneic Bone Marrow Transplantation," 1990-1992, \$10,000.
- 6) Co-Director, NCI grant P01-CA-23074, Clinical Research Inpatient of Cancer Center Support Grant, 1989-1994, \$204,261.
- 7) Principal Investigator, Knoll Pharmaceutical Co., "Dex-Verapamil as a Reversing Agent in Drug-Resistant Multiple Myeloma," 1992-1994, \$48,000.
- 8) Principal Investigator, Vertex Pharmaceutical Co., "Investigation of Novel Chemosensitizers to Reverse Multidrug Resistance," 1993-1994, \$46,500.
- 9) Principal Investigator, NCI grant R01-43043-07, "Mechanisms of Drug-Resistance in Multiple Myeloma" 1992-1995, \$149,000/year.
- 10) Project Leader, NCI grant P01-41183-05, "Clinical Correlations of Chromosome Change in Human Breast Cancer", 1990-1995, \$381,276.
- 11) Project Leader, Arizona Disease Control Research Commission, "Breast Cancer and Drug Resistance." 1994-1997, \$180,000.
- 12) Principal Investigator, Sandoz Pharmaceuticals Corporation, "Phase I Study of Vincristine, Doxorubicin, Dexamethasone (VAD) and SDZ833 Therapy in Subjects with Refractory or Relapsed Multiple Myeloma or Low Grade Non-Hodgkin's Lymphoma (PSCB154)," \$53,938, 1995.
- 13) Principal Investigator, Sandoz Pharmaceuticals Corporation, "A Study of PSC833 with Cytosine Arabinoside and Daunorubicin in Patients with Poor Prognosis Acute Myelogenous Leukemia," \$22,350, 1995.
- 14) Principal Investigator, CellPro, Inc., "A Multi-Center, Randomized, Controlled Phase III Study Evaluating CD34 Selected vs. Unselected, Autologous Peripheral Blood Progenitor Cell Transplantation in Patients with Multiple Myeloma," \$30,000, 1995.
- 15) Principal Investigator, Parke-Davis Pharmaceuticals, "Phase II Study of CI-958 in Patients with Advanced Myeloma Followed by CI-958 plus Cyclosporine A (CSA) in Patients Resistant to CI-958 Alone," 1995.
- 16) Principal Investigator, Glaxo Research Institute, "A Co-Administration of Rising Oral GG918 (GF120918) Dose Levels with Doxorubicin Phase I Study in Patients with Cancer," \$284,702, 1995.
- 17) Principal Investigator, NCI Grant P01-CA-17094-17, "Medical Oncology Program Project," 1994-1996, \$1,448,098.
- 18) Principal Investigator, Cell Therapeutics, Inc., "Lysofylline as an Agent to Prevent Emergence of Drug Resistance," 1997, \$45,000.
- 19) Project Leader, NCI Grant PO1 CA 17094-17, "Medical Oncology Program Project", 1997-1998, (SE Salmon, P.I.), \$1,448,098, 20% effort.

- 20) Principal Investigator, Vertex study, "VX-710 as a chemosensitizer in prostate cancer," \$106,188, 1998.
- 21) Principal Investigator, Cure for Lymphoma Foundation, "The Role of Fas/Fas Ligand Mediated Apoptosis in the Pathogenesis of Non-Hodgkin's Lymphoma," 1998-1999, \$35,000. (Salary support for T. Landowski, Ph.D.).
- 22) Principal Investigator, NCI/Frontier Science, U19 CA21115-01, "Mechanisms of Drug Resistance in Hematologic Malignancies," \$40,776, 1999.
- 23) Principal Investigator, Novartis Zoledronate study in myeloma & breast, 4244603010, \$72,210, 1999.
- 24) Principal Investigator, NCI/Frontier Science U10 CA21115-01, "Correlative Lab Studies for ECOG E1A95," \$6,887, 1999.
- 25) Principal Investigator, Parke-Davis, "A Multi-center Phase II Study of Oral N-ACETYL Dianiline in the Treatment of Patients with Advanced Myeloma," 1997-2000, \$38,500.
- 26) Co-Investigator, NIH/NCI P30 CA 76292-01, "Cancer Center Support Grant", 1997-2000, (J. Ruckdeschel, P.I.) \$1,031,430, 15% effort.
- 27) Principal Investigator, NCI P01 CA 82533, "MOPP: Molecular Oncology Program Project", \$941,431 (year 1), 2000-2001, 10% effort for administration of P01 grant.

CURRENT FUNDING:

- 1) Principal Investigator, NIH/NCI Grant R01 CA 77859-01, "Drug Resistance in Multiple Myeloma," 1998-2006, \$225,000 (year 4); 20% effort.
- 2) Principal Investigator, NIH/NCI P30 CA 76292, "Cancer Center Support Grant", 2001-2006,
- 3) Project Leader, NCI P01 CA 82533, "MOPP Project I: Cell Adhesion-Mediated Drug Resistance (CAM-DR)," \$164,814 (year 1), 2000-2005, 20% effort.
- 4) Co-Investigator, NCI CA 76292, "FTI Phase II Trials: Correlative Laboratory Studies," 1999-2000, (S. Sebt, P.I.) \$92,200, 10% effort.
- 5) Co-Investigator, NCI R01, CA 839978-01, "Farnesyl transferase inhibitors in cancer therapy: Bench to Bedside," (S. Sebt, P.I.) \$241,708 (year 1), 2000-2004, 5% effort.
- 6) Project Leader, Multiple Myeloma Research Foundation, DFCI Program Grant, "The Influence of the Microenvironment on Treatment Response and Drug Resistance (Project 2), \$108,000 (year 1) 2001-2003.

PENDING FUNDING

- 1) Co-Investigator, NCI R01, "Protection Established Tumors Have from T-Cell Rejection," \$125,000, 2000-2005.
- 2) Co-Investigator, DFCI, SPOR Grant, "Development of Novel Target-Based Therapies for Multiple Myeloma." \$110,000 (year 1) 2002-2004.

PATENTS:

- 1) Inhibition of STAT3 Signal Transduction For Human Cancer Therapy, (patent pending), serial #60/117,600, Jove R, Dalton, WS, Sebt S, Yu H, January, 1999.
- 2) Method of Modulating Cell Adhesion Mediated Drug Resistance (CAM-DR) and Therapeutic Uses Thereof, (patent pending), Dalton WS, Damiano J, Cress A, November, 1999.

PUBLICATIONS:

Book Chapters:

1. Dalton WS and Alberts DS: Physiologic disposition and phase I studies of mitoxantrone. In : Pharmanal --A Comprehensive Guide to the Therapeutic Use of Mitoxantrone. Chapter 3, pp 75-86, Chicago: Sieber & McIntyre, Inc., Pharma Libri Division, 1984.
2. Dalton WS and Alberts DS: Pharmacokinetics of mitoxantrone. In: Pharmanal -- A Comprehensive Guide to the Therapeutic Use of Mitoxantrone. Chapter 1, pp 5-18, Chicago: Sieber & McIntyre, Inc., Pharma Libri Division, 1986.
3. Dalton WS, Brooks RJ, Jones SE, Salmon SE, Ketchel SJ, Giordano GF, Jackson RA, Mosley K, and Slymen D: Breast cancer adjuvant therapy trials at the Arizona Cancer Center using Adriamycin and Cyclophosphamide. In: Salmon SE (ed.). Adjuvant Therapy of Cancer V. Chapter, pp 263-269, Grune and Stratton, Inc., 1987.

4. Trent JM, Yang JM, Thompson FH, Leibovitz A, Villar H, **Dalton WS**: Chromosome alterations in human breast cancer. In: Slyuser M (ed.). Oncogenes and Hormones in Breast Cancer, Chapter 7, pp 142-151, Ellis Horwood Ltd. 1987.
5. Trent JM, Meltzer PS, Slovak ML, Hill AB, **Dalton WS**, Beck WT, Cole S: Cytogenetic and molecular biologic alterations associated with anthracycline resistance. In: Woolley P and Tew K (eds.). Proceedings: Ninth Annual Bristol-Myers Symposium on Cancer Research: Mechanisms of Drug Resistance in Neoplastic Cells. Academic Press, Inc., 1988.
6. Salmon SE, Grogan T, Scheper R, Meltzer PS, **Dalton WS**: Relevance of multidrug resistance to neo-adjuvant therapy of cancer. In: Jacquillat CI, Weil M, Khayat D (eds). Neo Adjuvant Chemotherapy. Vol 169, pp 17-23, Paris: INSERM/John Libbey Eurotext Ltd., 1988.
7. Alberts DS, Peng YM, Bowden GT, Mackel C, **Dalton WS**: Mechanisms of action and pharmacokinetics of Novantrone® in intravenous and intraperitoneal therapy. Chapter, pp 15-21, Lederle Laboratories Monograph Series, 1988.
8. **Dalton WS**, Miller TP: Multidrug Resistance. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds.), Cancer: Principles and Practice of Oncology, PPO Updates. Vol 5(7), pp 1-13, Philadelphia: J. B. Lippincott, July, 1991.
9. **Dalton WS**, Management of systemic metastases and sequential therapy for advanced disease. In: Bland KI and Copeland III EM (eds.). The Breast: Comprehensive Management of Benign and Malignant Diseases. Chapter 42, pp 877-899, Philadelphia: W.B. Saunders Company, 1991.
10. **Dalton WS**, Grogan TM, Miller TP: The role of P-glycoprotein in drug-resistant hematologic malignancies. In: R.F. Ozols (ed.). Molecular and Clinical Advances in Anticancer Drug Resistance. Chapter 9, pp 187-208, Boston: Kluwer Academic Publishers, 1991.
11. Salmon SE, Grogan TM, Miller TP, Lehnert M, **Dalton WS**. Clinical detection of multidrug resistance and reversal with chemosensitizing agents. In: Drug Resistance as a Biochemical Target in Cancer Chemotherapy. Proceedings: 13th Annual Bristol-Myers Squibb Symposium on Drug Resistance. Chapter 14, pp 257-269, Academic Press, Inc., 1992.
12. **Dalton WS**, Salmon SE: Drug resistance in myeloma: Mechanisms and approaches to circumvention. In: Barlogie B (ed.). Hematology/Oncology Clinics of North America. Vol. 6, No. 2, pp. 383-393. Philadelphia: WB Saunders Co., April, 1992.
13. Futscher BW, **Dalton WS**: P-glycoprotein mediated multidrug resistance. In: Teicher B (ed.). Drug Resistance in Oncology. Chapter 19, pp. 461-478, New York: Marcel Dekker, Inc., April 1993.
14. Dorr RT, **Dalton WS**: Cancer chemotherapy in the elderly. In: Bressler R and Katz M (eds.). Geriatric Pharmacology. Chapter 22, pp 535-583, New York: McGraw-Hill, 1993.
15. **Dalton WS**: Overcoming the multidrug-resistant phenotype. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds.). Cancer: Principles and Practice of Oncology. Fourth Edition, pp 2655-2666, Philadelphia: J. B. Lippincott, 1993.
16. Bellamy WT, **Dalton WS**. Multidrug resistance in the laboratory and clinic. In: Advances in Clinical Chemistry. Vol 31, pp 1-61, 1994.
17. Shustik C, **Dalton W**, Gros P. P-glycoprotein mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. In: Molecular Aspects of Medicine. Vol 16, pp 1-78, Great Britain: Elsevier Science Ltd, 1995.
18. Beck WT, **Dalton WS**. Mechanisms of Drug Resistance. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds.) Cancer: Principles and Practice of Oncology. Fifth Edition, pp. 498-512, Philadelphia: J.B. Lippincott, 1995.
19. **Dalton WS**. The reversal of multidrug resistance. In: H.M. Pinedo and G. Giaccone (eds). Drug Resistance,

molecular mechanisms and clinical implications. Pp 232-244, Cambridge Univ. Press, 1998.

20. **Dalton WS**. Reversal of MDR in acute leukemias and non-Hodgkin's lymphoma. In: S. Gupta and T. Tsuruo (Eds.). Multidrug Resistance in Cancer Cells. Sussex, England: John Wiley & Sons, Ltd., 1997.
21. List AF, Glinsmann-Gibson B, **Dalton WS**. Pharmacologic modulation of multidrug resistance in acute leukemia: Results and Challenges. In: Hiddemann et al. (eds). Acute Leukemias V: Experimental Approaches and Management of Refractory Diseases. Vol. 36, Heidelberg: Springer-Verlag Publishers, Berlin Heidelberg, Germany, 1996.
22. Miller TP, Chase EM, **Dalton WS**, Grogan TM. The phenomenon of multidrug resistance in non-Hodgkin's lymphoma. In: F. Cabanillas and M.A. Rodriguez (eds.) Advances in lymphoma research. Pp 107-117. Boston: Kluwer Academic Publishers, 1997.
23. **Dalton WS**, Salmon S. New therapeutic approaches to myeloma. In: J. Berenson (ed.) Biology and Management of myeloma. Totowa: The Humana Press, (In Press), 1999.
24. Lądowski T, **Dalton WS**. Molecular Biology of Plasma Cell Disorders, Myeloma, (in press), 2001.
25. Shain, K, **Dalton WS**. The Role of the Bone Marrow Microenvironment in Multiple Myeloma Progression, Recent Advances in the Biology of Multiple Myeloma, (submitted), 2002.
26. Shain K, **Dalton WS**. Multiple Myeloma: A Story of Genes and The Environment, Principles of Molecular Medicine, (submitted), 2003.
27. Landowski T, **Dalton WS**. New Therapeutic Approaches to Myeloma, Berenson's Biology and Management of Multiple Myeloma, (submitted), 2003.

Invited Reviews/Editorials:

1. **Dalton WS**, and Alberts DS: Mitoxantrone: a promising new chemotherapeutic agent. *Ariz Med* 41(2):96-98, 1984.
2. **Dalton WS** and Durie BGM: Tumor cell kinetics: Implications for therapy. *Hosp Ther* 10(12):43-49, 1985.
3. **Dalton WS**: Rationale use of narcotic analgesics. *Hosp Ther* 10(9):45-60, 1985.
4. **Dalton WS**, Dalen JE: The role of high-dose therapy and autologous bone marrow transplantation in the treatment of cancer (Editorial). *AZ Med XLVI*(1):12, 1989.
5. **Dalton WS**, Miller TP, Salmon SE: Addition of verapamil to overcome drug resistance in multiple myeloma: preliminary clinical observations in 10 patients. [Letter, comment] *J Clin Oncol* 7(10):1578-1579, 1989.
6. Bellamy WT, **Dalton WS**, Dorr RT: The clinical relevance of multidrug resistance. [Review] *Cancer Investigation* 8:547-562, 1990.
7. **Dalton WS**: Mechanisms of drug resistance in breast cancer. [Review] *Seminars in Oncology* 17:37-39, 1990.
8. **Dalton WS**: Clinical and laboratory approaches to drug resistance. *Current Opinion in Oncology* 3:1043-1048, 1991.
9. **Dalton WS**, Grogan TM: Does P-glycoprotein predict response to chemotherapy, and if so, is there a reliable way to detect it? (Editorial) *J Natl Cancer Inst* 83(2):80-81, 1991.
10. Fondriest JE, Pitt MJ, William WH, **Dalton WS**: Radiologic abnormalities at the harvest site in patients undergoing bone marrow transplantation. [letter]. *American Journal of Roentgenology* 159: 226, 1992.
11. **Dalton WS**: Drug resistance modulation in the laboratory and the clinic. [Review] *Seminars in Onc* 20(1):64-69,

1993.

12. **Dalton WS:** Is P-glycoprotein a potential target for reversing clinical drug resistance? *Current Opinion in Oncology*, 6:595-600, 1994.
13. **Dalton WS, Sikic B:** Controversies in science: The multidrug-resistance gene (MDR1) represents a potential target for reversing drug resistance in human malignancies. [Editorial] *J Natl. Inst. Health*, 6:54-61; 1994.
14. **Dalton WS:** Therapeutic modalities. [Editorial] *Current Opinion in Oncology*, 7:531, 1995.
15. **Dalen JE, Dalton WS:** Does cholesterol lowering cause cancer? [Editorial] *JAMA*, 275(1):67-69, 1996.
16. **Dalton WS, Rosen S:** Therapeutic modalities. [Editorial] *Current Opinion in Oncology*, 9:541-542, 1997.
17. **Dalton WS:** Introduction, Drug resistance in hematologic malignancies. [Editorial] *Seminars in Hematology*, 34(4):1-2, 1997.
18. **Dalton WS:** Overview of the advances in the treatment of multiple myeloma. [Editorial] *Cancer Control Journal*, 5(3):95-96, 1998.
19. **Dalton WS, Rosen S:** Therapeutic modalities. [Editorial] *Current Opinion in Oncology*, 10:523-524, 1998.
20. **Dalton WS, Scheper RJ.** Lung resistance-related protein: Determining its role in multidrug resistance. [Editorial] *Journal National Cancer Institute* 91(19): 1604-1605, 1999.
21. **Dalton WS.** What is Multiple Myeloma? www.BestDoctors.com (copyright 2000)
22. **Dalton WS.** Cellular determinants of drug resistance provide new targets for cancer therapy. *Curr. Opinion in Oncology* 12:541-2, 2000.
23. **Dalton WS.** Therapeutic modalities. *Current Opinion in Oncology* 13:451-452, 2001.
24. **Dalton WS.** Drug Resistance and Drug Development in Multiple Myeloma. *Seminars in Oncology*. (In Press 10/02)
25. **Dalton WS.** Targeting the mitochondria: an exciting new approach to myeloma therapy. [Editorial] *Clinical Cancer Research*. (In Press 10/02)
26. **Dalton WS.** Proteasome inhibition: a new pathway in cancer therapy. *Cancer Treatment Reviews* 29 (Suppl. 1):1-2, 2003.

Refereed Journal Articles:

1. **Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB:** Effects of marijuana combined with secobarbital. *Clin Pharmacol Ther* 18:298-304, 1975.
2. **Petersen BH, Graham J, Lemberger L, Dalton WS:** Alterations in the cellular-mediated immune responsiveness of chronic marijuana smokers. *Psychopharmacol Commun* 1:67-74, 1975.
3. **Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB:** Influence of cannabidiol on delta-9-tetrahydrocannabinol. *Clin Pharmacol Ther* 19:300-309, 1976.
4. **Lemberger L, Dalton WS, Martz R, Rodda BE, Forney RB:** Clinical studies on the interaction of psychopharmacologic agents with marihuana. *New York Acad Sci* 281-219-228, 1976.
5. **Dalton WS, Martz R, Rodda BE, Lemberger L, Forney RB:** Influence of cannabidiol on secobarbital effects and plasma kinetics. *Clin Pharmacol Ther* 20:695-700, 1976.

6. O'Neil JD, **Dalton WS**, Forney RB: The effect of cannabichromene on the mean blood pressure, heart rate, and respiration rate responses to tetrahydrocannabinol in the anesthetized rat. *Toxicol Appl Pharm* 49:265-270, 1979.
7. Johnson JM, Lemberger L, Novotny M, Forney RB, **Dalton WS**, Maskarinec MP: Pharmacological activity of the basic fraction of marihuana whole smoke condensate alone and in combination with delta-9-tetrahydrocannabinol in mice. *Toxicol Appl Pharm* 72(3):440-448, 1984.
8. Alberts DS, Peng YM, Bowden GT, **Dalton WS** and Mackel C: Pharmacology of mitoxantrone: Mode of action and pharmacokinetics. *Invest New Drugs* 3:101-107, 1985.
9. Garewal HS and **Dalton WS**: Metoclopramide in vincristine-induced ileus. *Cancer Treat Rep* 69:1309-1311, 1985.
10. **Dalton WS**, Durie BGM, Alberts DS, Gerlach JH, Cress AE: Characterization of a new drug resistant human myeloma cell line that expresses P-glycoprotein. *Cancer Res* 46:5125-5130, 1986.
11. Dorr RT, Liddil JD, Trent JM, **Dalton WS**: Mitomycin C resistant L1210 leukemia cells: Association with pleiotropic drug resistance. *Biochem Pharmacol* 36:3115-3120, 1987.
12. **Dalton WS**, Cress AE, Alberts DS, Trent JM: Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. *Cancer Res* 48:1882-1888, 1988.
13. Durie BGM and **Dalton WS**: Reversal of drug-resistance in multiple myeloma with verapamil. *Br J Haematol* 68:203-206, 1988.
14. Slovak ML, Hoeltge GA, **Dalton WS**, Trent JM: Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. *Cancer Res* 48:2793-2797, 1988.
15. Cress AE, Roberts RA, Bowden GT, **Dalton WS**: Modification of keratin by the chemotherapeutic drug mitoxantrone. *Biochemical Pharmacology*:
16. Bellamy WT, Dorr RT, **Dalton WS**, Alberts DS: Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. *Cancer Res* 48:6360-6364, 1988.
17. Bellamy WT, **Dalton WS**, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, Alberts DS: Verapamil reversal of doxorubicin resistance in multidrug resistant human myeloma cells and association with drug accumulation and DNA damage. *Cancer Res* 48:6365-6370, 1988.
18. Bellamy WT, **Dalton WS**, Meltzer P, Dorr RT: The role of glutathione and its associated enzymes in multidrug resistant human myeloma cells. *Biochem Pharmacol* 38:787-793, 1989.
19. **Dalton WS**, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. *J Clin Oncol* 7(4):415-424, 1989.
20. Salmon SE, Soehnlen B, **Dalton WS**, Meltzer P, Scuderi P: Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. *Blood* 74(5):1723-1727, 1989.
21. Peng YM, **Dalton WS**, Alberts DS, Xu MJ, Lim H, Meyskens FL: Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. *Intl J Cancer* 43:22-26, 1989.
22. Tong AW, Lee J, Wang R-M, **Dalton WS**, Tsuruo T, Fay JW, Stone MJ: Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody. *Cancer Res* 49:4829-4834, 1989.
23. **Dalton WS**, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman H, Pinedo HM, Salmon SE:

- Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation. *Blood* 73(3):747-752, 1989.
24. Salmon SE, Grogan TM, Miller T, Scheper R, **Dalton WS**: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. *J Natl Cancer Inst* 81(9):696-701, 1989.
 25. Harker WG, Slade DL, **Dalton WS**, Meltzer PS, Trent JM: Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. *Cancer Res* 49:4542-4549, 1989.
 26. Roberts RA, Cress AE, **Dalton WS**: Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. *Biochem Pharm* 38:4283-4290, 1989.
 27. Robert NJ, **Dalton WS**, Osborne CK, Abeloff M. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. *Hormone Research* 32 Suppl 1: 221-222, 1989.
 28. Modiano MR, **Dalton WS**, Lippman SM, Joffe L, Booth AR, Meyskens FL: Ocular toxic effects of fenretinide. *J Natl Cancer Inst* 82(12):1063, 1990.
 29. Tong AW, **Dalton WS**, Tsuruo T, Fay JW, Stone MJ: Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement. *Prog Clin Biol Res* 333:155-64, 1990.
 30. Modiano MR, **Dalton WS**, Lippman SM, Joffe L, Booth AR, Meyskens, FL: Phase II study of fenretinide (N-[4-hydroxyphenyl]Retinamide) in selected advanced malignancies. *Investigational New Drugs* 8:317-319, 1990.
 31. Grogan T, **Dalton W**, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S: Optimization of immunocytochemical p-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. *Lab Invest* 63(6):815-824, 1991.
 32. Lehnert M, **Dalton WS**, Roe D, Emerson S, Salmon SE: Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. *Blood* 77(2):348-354, 1991.
 33. Pennock GD, **Dalton WS**, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE: Systemic toxic effects associated with high dose verapamil infusion and chemotherapy administration. *J Natl Cancer Inst* 83(2):105-110, 1991.
 34. Salmon SE, **Dalton WS**, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP: Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. *Blood* 78(1): 44-50, 1991.
 35. Miller TP, Grogan TM, **Dalton WS**, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. *J Clin Oncol* 9(1):17-24, 1991.
 36. Bellamy WT, **Dalton WS**, Gleason MC, Grogan TM, Trent JM: Development and characterization of a melphalan resistant human multiple myeloma cell line. *Cancer Res* 51:995-1002, 1991.
 37. Scheper RJ, **Dalton WS**, Grogan TM, Schlosser A, Bellamy WT, Taylor CW, Scuderi P, Spier C: Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LK-mediated cytotoxicity. *Int J Cancer* 48:562-567, 1991.
 38. Taylor CW, **Dalton WS**, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. *Br J Cancer* 63:923-929, 1991.
 39. Meltzer P, Leibovitz A, **Dalton W**, Villar H, Kute T, Davis J, Nagle R, Trent J: Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. *Br J Cancer* 63:727-735, 1991.

40. List AF, Spier CM, **Dalton WS**. Multidrug resistance and its circumvention in acute leukemia. *Haematology and Blood Transfusion* 34:3-10, 1992.
41. Futscher BW, Pieper RO, **Dalton WS**, Erickson LC. Gene-specific DNA interstrand cross-links produced by nitrogen mustard in the human tumor cell line Colo320HSR. *Cell Growth and Differentiation* 3(4):217-223, 1992.
42. Futscher BW, Campbell K, **Dalton WS**: Collateral sensitivity of nitrosoureas in multidrug-resistant cells selected with verapamil. *Cancer Res* 52:5013-5017, 1992.
43. Bensinger WI, Buckner CD, Clift RA, Petersen FB, Bianco JA, Singer JW, Appelbaum FR, **Dalton WS**, Beatty P, Fefer A, Storb R, Thomas ED, Hansen JA: Phase I study of Busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. *J Clin Oncol* 10(9):1492-1497, 1992.
44. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski JA, Weinstein RS, Scheper RJ, **Dalton WS**. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. *Blood* 81(2):490-495, 1993.
45. Bellamy WT, Odeleye A, Finley P, Huizenga E, **Dalton WS**, Weinstein RS, Hersh EM, Grogan TM: An *in vivo* model of human multidrug resistant multiple myeloma in SCID mice. *Am J Pathol* 142(3):691-697, 1993.
46. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, **Dalton WS**, Heijningen THMv, Kalken CKv, Slovak ML, Vries GEd, Valk, Pvd, Meijer CJLM, and Pinedo HM: Overexpression of a M_r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. *Cancer Research* 53:1475-1479, 1993.
47. Thompson F, Emerson J, **Dalton WS**, Yang J-M, McGee D, Villar H, Knox S, Massey K, Weinstein R, Bhattacharyya A, Trent J: Clonal chromosome abnormalities in human breast carcinomas I. Twenty-eight cases with primary disease. *Genes, Chromosomes and Cancer* 7:185-193, 1993.
48. Trent J, Yang J-M, Emerson J, **Dalton WS**, McGee D, Massey K, Thompson F, Villar H: Clonal chromosome abnormalities in human breast carcinomas II. Thirty-four cases with metastatic disease. *Genes, Chromosomes and Cancer* 7:194-203, 1993.
49. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, **Dalton W**: Phase I/II trial of Cyclosporine as a chemotherapy-resistance modifier in acute leukemia. *Journal of Clinical Oncology*, 11(9): 1652-1660, 1993.
50. Futscher BW, Blake LL, Gerlach TM, Grogan TM, **Dalton WS**. Quantitative polymerase chain reaction analysis of *mdr1* mRNA in multiple myeloma cell lines and clinical specimens. *Analytical Biochem*, 213: 414-421, 1993.
51. Leyland-Jones B, **Dalton W**, Fisher GA, Sikic BI: Reversal of multidrug resistance to cancer chemotherapy. [review]. *Cancer*, 72(11): 3484-3488, 1993.
52. Lehnert M, Emerson S, **Dalton WS**, de Giuli R, Salmon SE: In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. *Journal of the National Cancer Institute Monographs* No. 15, 1993.
53. Emerson JC, Salmon SE, **Dalton W**, McGee DL, Yang JM, Thompson FH, Trent JM. Cytogenetics and clinical correlations in breast cancer. *Adv Exp Med Biol*, 330: 107-118, 1993.
54. Weinstein RS, Hansen KK, McBeath RB, **Dalton WS**. Expression of the MDR1 gene (P-glycoprotein) in breast cancer. *Recent Results Cancer Res*, 127: 49-54, 1993.
55. Bauman PA, **Dalton WS**, Anderson JM, Cress AE. Expression of cytokeratin confers multiple drug resistance. *Proc. Natl. Acad. Sci. USA* 91: 5311-5314, 1994.
56. Klimecki WT, Futscher BW, Grogan TM, **Dalton WS**: P-glycoprotein expression and function in circulating blood cells from normal volunteers. *Blood*, 83(9): 2451-2458, 1994.

57. Futscher BW, Abbaszadegan MR, Domann F, **Dalton WS**: Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. *Biochem Pharmacol*, 47(9): 1601-1606, 1994.
58. Taetle R, Dos Santos B, Ohsugi Y, Koishihara Y, Yamada Y, Messner H, **Dalton W**: Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma. *J Natl Cancer Inst*, 86(6): 450-455, 1994.
59. Klimecki WT, Futscher BW and **Dalton WS**: Effects of ethanol and paraformaldehyde on RNA yield and quality. *Biotechniques*, 16:1021-1023, 1994.
60. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, **Dalton WS**: Analysis of multidrug resistance-associated protein (MRP) mRNA in normal and malignant hematopoietic cells. *Cancer Res*, 54: 4676-4679, 1994.
61. Haddad G, Thorner PS, Bradley G, **Dalton WS**, Ling V, Chan HSL: A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow. *Laboratory Investigation*, 71(4): 595-603, 1994.
62. Glasser L, Fiederlein RL, Wood M, **Dalton WS**, List A. Hematopoietic progenitor cell content of bone marrow harvests: Relative contributions of blood and bone marrow. *Prog Clin Biol Res* 389:621-630, 1994.
63. Guan XY, Meltzer PS, **Dalton WS**, Trent JM: Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. *Nature Genetics* 8(2):155-161, 1995.
64. Klimecki WT, Taylor CW, **Dalton WS**: Inhibition of cell mediated cytotoxicity and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. *J Clin Immunol* 15(3):152-158, 1995.
65. Bellamy WT, Odeleye A, Huizenga E, **Dalton WS**, Weinstein RS, Grogan TM: Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts. *Clin Cancer Res* 1(12):1563-1570, 1995
66. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg JH, Appelbaum F, Singer JW, Flomenberg N, **Dalton W**, Elfenbein GJ, Rifkin R, Rubin A, Agosti J, Hayes FA, Holcenberg J, Shadduck RK: Phase III randomized, double-blind, placebo controlled trial of rhGM-CSF following allogeneic bone marrow transplant. *Bone Marrow Transplantation* 15:949-954, 1995.
67. **Dalton WS**, Crowley JJ, Salmon SE, Grogan TM, Laufman LR, Weiss GR, Bonnet JD. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance for patients with refractory myeloma: a southwest oncology group study. *Cancer*, 75(3):815-820, 1995.
68. Anderson JM, Heindl LM, Bauman PA, Ludi CW, **Dalton WS**, Cress AE: Cytokeratin expression results in a drug resistant phenotype to six different chemotherapeutic agents. *Clin Cancer Res*, 2:97-105, 1996.
69. Witherspoon SM, Emerson DL, Kerr BM, **Dalton WS**, Wissell PS: Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug inhibitor GG918. *Clinical Cancer Research*, 2:7-12, 1996.
70. Salmon SE, **Dalton WS**. Relevance of multidrug resistance to rheumatoid arthritis: Development of a new therapeutic hypothesis. *The Journal of Rheumatology*, 23(44):97-101, 1996.
71. Glasser L, **Dalton WS**, Fiederlein RL, Cook P, Powis G, Vogler WR. Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid. *Exper Hem* 24(2):253-257, 1996.
72. Futscher BW, Foley N, Gleason-Guzman M, Meltzer PS, Sullivan DM, **Dalton WS**. Verapamil suppresses the emergence of P-glycoprotein-mediated multidrug resistance. *Int. J. Cancer* 66(4):520-525, 1996.
73. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, **Dalton WS**. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. *Blood* 87(6):2464-2469, 1996.

74. Abbaszadegan MR, Foley NE, Gleason-Guzman MC, **Dalton WS**. Resistance to the chemosensitizer, verapamil, in a multidrug resistant (MDR) human multiple myeloma cell line. *International J. Cancer*, 66(4):506-514, 1996.
75. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates S, Berard CW, Boyett JM, Brophy N, Broxterman HJ, SL Chan H, **Dalton WS**, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimzsa L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, and Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance: Consensus recommendations. *Cancer Research* 56(13):3010-3020, 1996.
76. Lehnert M, Degiuli R, Kunke K, Emerson S, **Dalton WS**, Salmon SE. Serum can inhibit reversal of multidrug resistance by chemosensitizers. *Eur J Cancer* 32A(5):862-867, 1996.
77. Zhao S, Consoli U, Arceci R, Pfeifer J, **Dalton WS**, Andreeff M. A new semi-automated PCR method for quantitating MDR1 expression. *Biotechniques* 21:726-731, 1996.
78. Vogler WR, Berdel WE, Geller RB, Brochstein JA, Beveridge RA, **Dalton WS**, Miller KB, Lazarus HM. A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. *Adv Exp Med Biol* 416:389-396, 1996.
79. Cress AE, **Dalton WS**. Multiple drug resistance and intermediate filaments. *Cancer and Metastasis Rev* 15:499-506, 1996.
80. Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, **Dalton, WS**. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. *Cancer Res* 56:5435-5442, 1996.
81. Taylor CW, **Dalton WS**, Mosley K, Dorr RT, Salmon SE. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus quinine and verapamil in patients with advanced breast cancer. *Breast Cancer Research and Treatment* 42:7-14, 1997.
82. Cellier M, Shustik C, **Dalton WS**, Rich E, Hu J, Malo D, Schurr E, Gros P. Expression of the human NRAMP 1 gene in professional primary phagocytes: studies in blood cells and in HL-60 promyelocytic leukemia. *J Leukoc. Biol.* 61:96-105, 1997.
83. Landowski TH, Guzman MG, **Dalton WS**: Selection for drug resistance results in resistance to Fas-mediated apoptosis. *Blood* 89:1854-1861, 1997.
84. Taylor CW, Green S, **Dalton WS**, Martino S, Rector D, Ingle JN, Robert N, Budd GT, Paradelo JC, Natale RB, Bearden JD, Mailliard JA, Osborne CK. Multi-center, randomized clinical trial of goserelin versus surgical ovariectomy in pre-menopausal patients with receptor positive metastatic breast cancer: an intergroup study. *J Clin Onc* 16:994-999, 1998.
85. **Dalton WS**. Mechanisms of drug resistance in hematologic malignancies. *Seminars in Hematology* 34:3-8, 1997.
86. Chan HSL, Haddad G, Zheng L, Bradley G, **Dalton WS**, Ling W. Sensitive immunofluorescence detection of the expression of P-glycoprotein in malignant cells. *Cytometry* 29:65-75, 1997.
87. Watts GS, Pieper RO, Costello JF, Peng YM, **Dalton WS**, Futscher BW. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. *Molecular Cell Biology* 17:5612-5619, 1997.
88. **Dalton WS**. Detection of multidrug resistance gene expression in multiple myeloma. *Leukemia* 11:1166-1169, 1997.
89. **Dalton WS**. Alternative (Non-P-Glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma. *Hematol Clin N Amer* 11:975-986, 1997.

90. Landowski TH, Qu N, Buyuksal I, Painter JS, **Dalton WS**. Mutations in the Fas antigen in patients with multiple myeloma. *Blood* 90:4266-4270, 1997.
91. Wang H, Jiang Zg, Wong YW, **Dalton WS**, Futscher BW, Chan VTW. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase II alpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. *Biochem Biophys Commun* 237:217-224, 1997.
92. Collins RH, Jr., Shpilberg O, Drobyski WR, Porter DL, Giral S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, **Dalton W**, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. *J Clin Oncol* 15:433-444, 1997.
93. Hazlehurst LA, Gros P, **Dalton WS**. Chromosome mediated gene transfer of drug resistance to mitoxantrone. *Anti-Cancer Res* 18:1005-1010, 1998.
94. Lamy T, Liu JH, Landowski TH, **Dalton WS**, Loughran TP. Dysregulation of Fas/Fas ligand-apoptotic pathway in CD3+ large granular lymphocyte (LGL) leukemia. *Blood* 92:4771-4777, 1998.
95. Izbicka E, **Dalton WS**, Troyer D, Van Hoff DD. Expression of two multidrug resistance genes in human prostatic carcinomas. *J Natl Cancer Inst* 90:166-167, 1998.
96. Miller TP, Chase EM, Dorr R, **Dalton WS**, Lam KS, Salmon SE. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. *Anticancer Drugs* 9:135-140, 1998.
97. Kickhoefer VA, Rajavel KS, Scheffer GL, **Dalton WS**, Scheper RJ, and Rome LH. Vaults are up-regulated in multidrug-resistant cancer cell lines. *J Biol Chem* 273:8971-8974, 1998.
98. Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, **Dalton WS** et al. Broadened clinical utility of gene gun-mediated granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. *Human Gene Therapy* 9:1121-1130, 1998.
99. Landowski TH, Shain KH, Oshiro MM, Buyuksal I, Painter JS, **Dalton WS**. Myeloma cells selected for resistance to Fas mediated apoptosis are not cross-resistant to cytotoxic drugs: Evidence for independent mechanisms of caspase activation. *Blood* 94:265-274, 1999.
100. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, **Dalton WS**. Cell adhesion mediated drug resistance (CAM-DR): Role of β_1 integrins and resistance to apoptosis in human myeloma cell lines. *Blood* 93:1658-1667, 1999.
101. Hazlehurst LA, Foley NF, Guzman-Gleason MC, Cress AE, Hacker MP, Greenberger LW, de Jong MC, **Dalton WS**. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. *Cancer Res* 59:1021-1028, 1999.
102. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Nunez G, **Dalton WS**, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human myeloma tumor cells. *Immunity* 10:105-115, 1999.
103. Shtil A, Turner J, Durfee J, **Dalton WS**, Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T-lymphocytes. *Blood* 93:1831-1837, 1999.
104. Ross DD, Yang W, Abruzzo LV, **Dalton WS**, Schneider E, Lage H, Dietel M, Greenberger L, Cole S, Doyle LA. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. *Journal of the National Cancer Institute*, 91(5):429-33, 1999.
105. Rimza LM, Campbell K, **Dalton WS**, Salmon S, Wilcox G, Grogan TM. The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. *Leukemia and Lymphoma*, 34:315-24, 1999.

106. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, **Dalton W**, Jove R, Yu H. Gene therapy with dominant-negative STAT3 induces apoptosis and suppresses growth of the murine melanoma B16 tumor *in vivo*. *Can Research* 59:5059-5063, 1999.
107. Catlett-Falcone R, **Dalton WS**, Jove R. STAT proteins as novel targets for cancer therapy. *Curr Opin Onc*, 11:490-496, 1999.
108. **Dalton WS**. The tumor microenvironment as a determinant of drug response and resistance. *Drug Resistance Updates*, 2:285-288, 1999.
109. Burdelya L, Catlett-Falcone R, Levitzki A, Coppola D, **Dalton WS**, Jove R, Yu H. Interleukin-12 enhances the antitumor effect of the tyrosine kinase inhibitor AG-490 in a murine myeloma model. (submitted), 1999.
110. **Dalton WS**, Jove R, Yu H. Molecular determinants of treatment response in myeloma. 1999.
111. Bowman T, Yu H, Sebti S, **Dalton WS**, Jove R. Signal transducers and activators of transcription: novel targets for anticancer therapeutics. *Cancer Control*, 6:427-435, 1999.
112. **Dalton WS**, Jove R. Drug resistance in multiple myeloma: approaches to circumvention. *Semin in Onc*, 26:23-27, 1999.
113. Martinez-Zaguilan R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, **Dalton WS**, Gillies RJ. pH and drug resistance. I. Functional expression of plasmalemmal type H⁺-ATPase in drug resistant human breast carcinoma cell lines. *Biochem Pharmacol* 57:1037-1046, 1999.
114. Hazlehurst LA, Wisner L, **Dalton WS**. Increased nuclear translocation of the GR receptor as a major determinant of dexamethasone sensitivity in a MDR1 positive multiple myeloma cell line. (submitted), 2000.
115. Halgren RG, Krett NL, Pillay S, Painter JS, **Dalton WS**, Rosen ST. 8Cl-Adenosine causes apoptosis in drug resistant multiple myeloma cell lines. (submitted), 2000.
116. Diaz JI, Pow-Sang JM, Mora LB, Seigne JD, Cantor AB, **Dalton WS**. Cytometric analysis of fas expression in normal prostatic epithelium and prostate cancer. *Urologic Oncology*, 5: 149-154, 2000.
117. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, **Dalton WS**, Chin KV. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. *Cancer Research*, 60: 4161-4166, 2000.
118. Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger J, Schiller G, Pearce T, Litchman M, **Dalton WS**, Roe D, List AF. Phase I/II Study of the P-glycoprotein modulator PSC-833 (Valspodar) in patients with acute myeloid leukemia. *J Clin Oncol*. 19(6): 1589-99, 2001.
119. Shain K, Landowski T, Buyuksal I, Cantor A, **Dalton WS**. Clonal variability in CD95-expression is the major determinant in Fas-mediated, but not chemotherapy-mediated apoptosis in the RPMI 8226 multiple myeloma cell line. *Leukemia* 14:830-840, 2000.
120. Scheffer GL, Maliepaard M, Pijnenborg A, van Gastelen M, de Jong M, Schroeijers A, van der Kolk D, Allen J, Ross D, van der Valk P, **Dalton WS**, Schellens J, Scheper RJ. BCRP is localized at the plasma membrane in mitoxantrone and topotecan resistant cell lines. *Cancer Research* 60:2589-2593, 2000.
121. Shtil A, Turner J, **Dalton WS**, Yu H. Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes. *Leukemia & Lymphoma*, 38:59-70, 2000.
122. Damiano J, **Dalton WS**. Integrin-mediated drug resistance in multiple myeloma. *Leukemia & Lymphoma*, 38:71-81, 2000.

123. Hazlehurst L, Damiano J, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via $\beta 1$ integrins regulates p27^{kip1} levels and contributes to cell adhesion mediated drug resistance (CAM-DR). *Oncogene* 19:4319-4327, 2000.
124. Damiano J, Hazlehurst L, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ -irradiation. *Leukemia* Aug;15(8):1232-9, 2001.
125. Landowski TH, Moscinski L, Burke R, Buyuksal I, Painter J, Goldstein S, Dalton WS. CD95 antigen mutations in hematopoietic malignancies. *Leukemia & Lymphoma* 42:835-846, 2001.
126. Shain K, Landowski T, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for *de novo* drug resistance. *Curr. Opinion in Oncology* 12: 557-563, 2000.
127. Janssen WE, Dalton WS. Improved blood hematopoietic progenitor mobilization in myeloma patients following treatment with Thalidomide. (submitted), 2000.
128. Fishman MN, Dalton WS. Considerations in the management of myeloma. *Oncology* 14 (11A): 72-81, 2000.
129. Hazlehurst L, Valkov N, Wisner L, Storey J, Boulware D, Sullivan D, Dalton WS. Reduction in drug-induced DNA double-strand breaks associated with $\beta 1$ integrin-mediated adhesion correlates with drug resistance in U937 cells. *Blood* Sep 15;98(6):1897-903, 2001.
130. Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, Yu H. Overexpression of a dominant negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. *Cancer Res.* 61: 3276-3280, 2001.
131. Oshiro M, Landowski T, Catlett-Falcone R, Hazlehurst L, Huang M, Jove R, Dalton WS. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. *Clin Cancer Res* Dec;7(12):4262-71, 2001.
132. Grad JM, Bahlis NJ, Reis I, Oshiro M, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. *Blood* Aug 1;98(3):805-13, 2001.
133. Shain K, Landowski T, Dalton WS. Adhesion-mediated intracellular redistribution of c-fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. *Journal of Immunology*, 168:2544-2553, 2002.
134. Hazlehurst L, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. *Cancer & Metastasis Reviews* 20:43-50, 2001.
135. Shain K, Dalton WS. Cell adhesion is a key determinant in *de novo* multidrug resistance: New targets for the prevention of acquired multidrug resistance. *Molecular Cancer Therapeutics* 1:69-78, 2001.
136. Dalton WS, Bergasgel P, Kuehl W, Anderson K, Harousseau J. Multiple myeloma. *Hematology (Am Soc Hematol Educ Program)* Jan:157-77, 2001.
137. Anderson K, Kyle R, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst, L. Berenson J. Multiple Myeloma: New Insights and Therapeutic Approches. *Hematology (Am Soc Hematol Educ Program)*:147-165, 2000.
138. Bolick CE, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. *Leukemia* 17:451-457, 2003.
139. Huang M, Dorsey JF, Epling-Burnette PK, Landowski TH, Mora LB, Niu G, Sinibaldi D, Nimmanapalli R, Bai F, Kraker A, Yu H, Moscinski L, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of stat⁵ and growth of CML cells. *Oncogene* 21:8804-8816, 2002.

140. Nefedova Y, Landowski TH, **Dalton WS**. Bone marrow stromal-derived soluble factors and direct cell contact contribute to *de novo* drug resistance of myeloma cells by distinct mechanisms. *Leukemia* 17:1175-1182, 2003.
141. Alsina M, Gerbino E, Painter J, **Dalton WS**. The effects of interleukin-6 on myeloma cell adhesion to fibronectin are mediated by macrophage inflammatory protein-1 α . (Submitted), 2002
142. **Dalton WS**, Anderson K. Synopsis of a Research Roundtable Presented on Cell Signaling in Myeloma: Regulation of Growth and Apoptosis – Opportunities for New Drug Discovery. *Molecular Cancer Therapeutics*, 1:1361-1365, 2002.
143. Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, **Dalton WS**, Jove R, Yu H. Combination Therapy with AG-490 and Interleukin 12 Achieves Greater Antitumor Effects than Either Agent Alone. *Molecular Cancer Therapeutics*, 1:893-899, 2002.
144. Landowski TH, Olashaw NE, Agrawal D, **Dalton WS**. Cell Adhesion Mediated Drug Resistance (CAM-DR) is Associated with Activation of NF- κ B (RelB/p50) in Myeloma cells. *Oncogene* 22:2417-2421, 2003.
145. Rago RP, Einstein A, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, **Dalton WS**. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. *Cancer Chemother Pharmacol* 51:297-305, 2003.
146. **Dalton WS**. The tumor microenvironment: focus on myeloma. *Cancer Treatment Reviews* 29 (Suppl.1):11-19, 2003.
147. Alsina M, Fonseca R, Wilson EF, Belle N, Gerbino E, Price-Troska T, Overton R, Ahmman G, Bruzek L, Adjei A, Kaufmann S, Wright J, Sullivan D, Djulbegovic B, Cantor A, Greipp PR, **Dalton WS**, Sebti S. The Farnesyltransferase Inhibitor Zarnestra induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. (Submitted) 2003.
148. Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, **Dalton WS**. Genotypic and Phenotypic Comparisons of *de-novo* and Acquired Melphalan Resistance in an Isogenic Multiple Myeloma Cell Line Model. (Submitted) 2003.
149. Nefedova Y, Cheng P, Alsina M, **Dalton WS**, Gabrilovich DI. Notch-1 signaling mediates the influence of bone marrow stroma on myeloma cell survival and drug response. (Submitted) 2003.
150. Hazlehurst LA, Landowski TH, **Dalton WS**. The role of the tumor microenvironment in mediating *de-novo* resistance to drugs and physiological mediators of cell death. (Submitted) *Oncogene*, 2003.
151. The International Myeloma Working Group, including **Dalton WS**. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *British Journal of Hematology* 121:749-757, 2003.
152. Alsina M, Fonseca R, Wilson EF, Belle N, Gerbino E, Price-Troska T, Overton R, Ahmman G, Bruzek L, Adjei A, Kaufmann S, Wright J, Sullivan D, Djulbegovic B, Cantor A, Greipp PR, **Dalton WS** and Sebti SM. The Farnesyltransferase Inhibitor Zarnestra is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. (Submitted) 2003.
153. Burdelya L, Niu G, Zhong B, Zhang S, Shain K, **Dalton WS**, Djeu J, Sheng W, Yu H. Interrupting Stat3 Signaling in Tumor Cells Leads to Production of Soluble Factors that Induce Macrophage Nitric Oxide Production and Antitumor Effects. (Submitted) 2003.

Abstracts

1. **Dalton WS**, Martz R, Rodda BE, Lemberger L, Forney RB: Clinical effects of marijuana - Secobarbital combination.

The Pharmacologist, 1974.

2. Peterson BH, Graham J, Lemberger L, **Dalton WS**: Studies of the immune response in chronic marijuana smokers. The Pharmacologist, 1974.
3. Johnson JM, Lemberger L, **Dalton WS**, Forney RB: The effect of the acidic and basic fractions of marijuana whole smoke fractions on the THC induced hypothermia in mice. Toxicol Appl Pharm 48(1):A42, 1979.
4. **Dalton WS**, Cress AE, Trent JM, Alberts DS: Characterization of a mitoxantrone (DHAD) resistant human colon carcinoma cell line. Clin Pharm Ther, pg. 13 (#PL-11) 1985.
5. **Dalton WS**, Alberts DS, Robertone AB, Peng YM, Serokman R, Braich T, Garewal HS, Salmon SE: Indocyanine Green (ICG) for rapid prediction of 4'deoxydoxorubicin (Esoorubicin) pharmacokinetics, toxicity and dose selection. Proc Amer Soc Clin Oncol 4:36 (#C-136), 1985.
6. Alberts DS, Mackel C, Peng YM, **Dalton WS**, Weiner SA, Surwit EA, Young L, Salmon SE: Comparative activity of anticancer drugs used in high dose by the intraperitoneal (IP) route for the treatment of advanced ovarian cancer. Proc Amer Soc Clin Oncol 4:36(#C-137), 1985.
7. Alberts DS, Mackel C, Peng YM, **Dalton WS**, Weiner SA, Surwit EA, Young L, Salmon SE: Intraperitoneal chemotherapy of ovarian cancer: Comparative ratings of standard and experimental drugs based on in vivo pharmacokinetics and in vitro tumor sensitivity assays. 14th Intl. Congress of Chemother, Kyoto, Japan, 1985.
8. **Dalton WS**, Durie BGM, Gerlach J, Cress AE, Alberts DS, Ling V: Development and characterization of a new drug resistant human multiple myeloma cell line. Blood 66(5):220a(#766), 1985.
9. Meltzer P, **Dalton WS**, Kinzler K, Vogelstein B, Trent JM: DNA sequence amplification in a colon carcinoma cell line resistant to mitoxantrone. Proc. Amer. Soc. Clin. Oncol. 5:42(#C-162), 1986.
10. **Dalton WS**, Durie BGM, Grogan TM, Cress AE, Alberts DS: Cytogenetic and phenotypic analysis of a drug resistant human myeloma cell line. Proc AACR 27:271(#C-1074), 1986.
11. **Dalton WS**, Gleason M, McCloskey T, Durie BGM, and Alberts DS: Reversal of drug resistance in human multiple myeloma (MM) with verapamil (VER): Design of a clinical study based on in vitro testing using a drug resistant myeloma cell line. Proc. Amer. Soc Clin Oncol 6:31(#119), 1987.
12. Bellamy W, Dorr RT, Russell D, **Dalton WS**: Does drug accumulation entirely explain the phenomena of multidrug resistance (MDR)? Proc AACR 28:276 (#1093), 1987.
13. Meltzer P, Coccia M, Slovak M, **Dalton WS**, Beck W, Cole S, Trent J: Multidrug resistance (MDR) resulting from exposure to doxorubicin (DOX): evidence for genetic mechanisms not associated with P-glycoprotein amplification. Proc AACR 28:294(#1179), 1987.
14. Taylor C, **Dalton WS**, Bellamy W, Dorr RT, Cress A: Biochemical effects of hyperthermia on a doxorubicin resistant human myeloma cell line. Proc. AACR 28:276(#1092), 1987.
15. Peng YM, Lim H, **Dalton WS**, Alberts DS: Marked alteration in membrane transport and intracellular accumulation of vinblastine (VBS) in multi-drug resistant (MDR) human myeloma cells selected for resistance to doxorubicin (DOX). Proc. AACR 28:277(#1094), 1987.
16. Croghan M, Durie BGM, Vela E, **Dalton WS**, Tu F: Paradoxical increased sensitivity of chemotherapy resistant myeloma cells to the biologic agents TNF- α , TNF- β , IFN- α 2b plus corticosteroids. Proc AACR 28:404(#1603), 1987.
17. **Dalton WS**, Yang JM, Leibovitz A, Villar H, Thompson FH, Trent JM: Chromosome analysis and clinical correlation of human breast carcinoma. 10th Annual San Antonio Breast Cancer Symposium, December 1987.
18. Bellamy WT, Dorr RT, **Dalton WS**, Meltzer PS, Alberts DS: The role of glutathione (GSH) as a potential detoxification

system in multidrug-resistant (MDR) human myeloma cells. Proc AACR 29:317(#1259), 1988.

19. Liddil JD, Dorr RT, **Dalton WS**, Salmon SE: Correlation of multidrug-resistance (MDR) to recombinant tumor necrosis factor (rTNF) sensitivity based on lysosomal enzyme activity. Proc ASCO 7:50(#192), 1988.
20. Salmon SE, Grogan T, Scheper R, Meltzer PS, **Dalton WS**: Relevance of multidrug resistance to neoadjuvant therapy of cancer. Presented at 2nd International Congress on the Neoadjuvant Therapy of Cancer, Paris, February, 1988.
21. Bellamy WT, Dorr RT, **Dalton WS**, Alberts DS: Elevated glutathione levels in multidrug resistant human myeloma cells and its relationship to drug resistance. Annual Meeting of the Western Pharmacology Society, January 10-15, 1988.
22. Peng YM, Xu MJ, Lim H, **Dalton WS**, Alberts DS: Pharmacokinetics on N-4-Hydroxyphenyl-retinamide (4HPR) and effect of oral 4HPR patients. Third Intl Conf on Prevention of Human Cancer: Chemoprevention, January 12-15, 1988.
23. Peng YM, **Dalton WS**, Alberts DS, Booth A, Ponder R, Wargin W, and Tuttle R: Pharmacokinetics (PK) and phase I clinical trial of the arylmethylaminopropanediol (AMAP) crisnatol (Cris, BW A770U), a highly lipid soluble drug which distributes into the CSF. Proc AACR 29:194(#769), 1988.
24. Leibovitz A, **Dalton WS**, Massey K, Villar H, Trent J: Establishment and characterization of two new breast carcinoma cell lines from primary tumors. Proc. AACR 29:24(#96), 1988.
25. Einspahr J, Alberts DS, Gleason M, **Dalton WS**, Leibovitz A: Pharmacologic pitfalls in the case of the MTT (versus human tumor clonogenic-HTCA) assay to quantitate chemosensitization of human tumor cell lines. Proc AACR 29:492 (#1956), 1988.
26. Salmon SE, Lehnert M, Grogan T, Dorr R, **Dalton WS**: Verapamil (V) and quinine (Q) chemosensitive myeloma cells to doxorubicin (Dox) and vincristine (VCR) in vitro and are capable of reversing clinical relapses in multiple myeloma (MM). Blood 74(7):53a, 1989.
27. Tong AW, Want RM, **Dalton WS**, Fay JW, Stone MJ: Depletion of refractory myeloma clonogenic cells from primary bone marrow cultures by the plasma cell monoclonal antibody MM4 and complement. Blood 74(7):201a, 1989.
28. Robert NJ, **Dalton WS**, Osborn CK, Abeloff M: Therapy in premenopausal women with advanced, oestrogen positive Bor/and progesterone positive breast cancer: Surgical oophorectomy versus the LHRH analogue, Zoladex. Southwest Oncology Group, New England Medical Center, Boston, Mass. Horm 32(1):221-22, 1989.
29. Bellamy W, **Dalton WS**, Gleason M, Meltzer P, Spier C: Development of a doxorubicin (D) and verapamil (V)-resistant human myeloma cell line. Proc AACR 31:364(#2160), 1990.
30. Scheper RJ, **Dalton WS**, Grogan TM, Taylor CW, Scuderi P, Bellamy WJ, Schlosser A. Human multidrug-resistant (MDR) cells display undiminished sensitivity to both NK and LAK cell-mediated cytotoxicity. Proc AACR 31:272 (#1609), 1990.
31. Parrish PR, Cress AE, Gleason MC, Bellamy WT, **Dalton WS**: Enhanced drug efflux in mitoxantrone resistant human cells (MCF7/Mitox) is not attributed to P-glycoprotein (P-gp). Proc AACR 31:378 (#2241), 1990.
32. Lehnert M, Kunke K, **Dalton WS**, Roe D, Dorr RT, Salmon SE: In vivo concentration of serum proteins significantly inhibits reversal of P-glycoprotein-mediated drug resistance by some chemosensitizers. Proc AACR 31:379 (#2250), 1990.
33. **Dalton WS**: Reversing multidrug resistance in the laboratory and clinic. Proc AACR 31:520, 1990 (Plenary Session).
34. Paz B, Emerson JC, Thompson FH, Trent JM, **Dalton WS**, Villar HV: Clinical correlations of chromosome change in human primary breast cancer. Surgical Forum Annual, June 1990.

35. Grogan T, Guptill V, Scheper R, Spier C, **Dalton W**, Weinstein R: Altered cell adhesion molecule (CAM) expression in P-glycoprotein rich myeloma plasma cells. ASCB, 1990.
36. Yang MJ, Thompson FH, **Dalton W**, Villar H, Salmon SE, Trent JM: Cytogenetic findings in 122 cases of breast carcinoma. 4th International Workshop in Chromosomes in Solid Tumors, February 1991.
37. Futscher B and **Dalton W**: Ras mutations and IL6-dependence in human multiple myeloma cell lines. Proc AACR 32:47(#277), 1991.
38. Gleason M, Futscher B, **Dalton W**: Effects of interferon on drug cytotoxicity and growth kinetics in myeloma cell lines. Proc AACR 32:256(#1525), 1991.
39. Peng Y-S, Peng Y-M, **Dalton WS**, Alberts DS, Dyke RW: Binding of vincristine, vinblastine and vindesine to human α - and β -globulins, albumin and serum in vitro. Proc AACR 32:329(#1955), 1991.
40. Bellamy W, Gleason M, Futscher B, and **Dalton W**: Altered P-glycoprotein (P-170)-mediated doxorubicin (D) resistance in a verapamil (V)-resistant human multiple myeloma cell line. Proc AACR 32:367(#2181), 1991.
41. Scheper RJ, Broxterman BJ, Scheffer GL, **Dalton WS**, Dietel M, van Kolken CK, Slovak ML, deVries EGE, van der Valk P, Meijer CJLM, Pinedo SM: Different human multidrug-resistant (MDR) cell lines not expressing P-glycoprotein (P-gp) share a cytoplasmic protein recognized by monoclonal antibody LRP56. Proc AACR 32:370(#2198), 1991.
42. Lehnert M, Emerson S, Kunke K, **Dalton WS**, Salmon SE: Combined chemosensitization for reversing MDR1: Synergism of verapamil with quinine but antagonism with quinidine. Proc AACR 32:378(#2244), 1991.
43. Cress AE, Vernet LA, Bauman PA, Roberts RA, Sarid D, **Dalton WS**: Cytokeratin is a site of chemotherapeutic drug damage in a human colon tumor cell line. Proc AACR 32:398(#2365), 1991.
44. **Dalton WS**, List AF, Grogan TM, Miller TP, Salmon SE: Multidrug resistance in hematopoietic tumors. (Plenary Session) NCI EORTC, University of Amsterdam, March 17-20, 1992.
45. List AF, **Dalton WS**, Spier CS, Grogan TM, Miller TP, Salmon SE: Multidrug resistance in hemopoietic malignancy. 43rd Annual Meeting of The Histochemical Society, Bethesda, MD, May 15-16, 1992.
46. List AF, Spier C, Greer J, Azar C, Hutter J, Wolff S, Salmon S, Futscher B, **Dalton WS**: Biochemical modulation of anthracycline resistance (MDR) in acute leukemia with Cyclosporin-A (CSA). ASCO Annual Meeting, San Diego, CA, May 17-19, 1992.
47. **Dalton WS**, Birchfield G, Miller TP, Plezia P, Mosley K, Spigelman MK, Salmon SE. Phase I trial of R-verapamil as a chemosensitizing agent. Proc AACR 33:235, 1992.
48. Futscher BW, Blake LL, Grogan TM, **Dalton WS**. Quantitative PCR analysis of *mdr1* mRNA in patients with multiple myeloma. Proc AACR 33:467, 1992.
49. Futscher BW, Campbell K, **Dalton WS**. Collateral sensitivity to nitrosoureas in multidrug-resistant cells selected with verapamil. Proc AACR 33:467, 1992.
50. Hogan TF, Marx JJ, Krawisz BR, Spencer S, **Dalton WS**, Broxterman HJ, Scheper RJ. The human papillary renal carcinoma cell line ACHN exhibits broad "non-classic" multidrug resistance at both low and high passage levels, and expresses LRP56 antigen but not P-glycoprotein. Proc AACR 33:467, 1992.
51. Klimecki WT, Futscher BW, Blake LL, Grogan TM, **Dalton WS**: Lineage restricted *mdr1* expression in normal blood cells. Proc AACR 33:467, 1992.
52. Lehnert M, Emerson S, **Dalton WS**, Salmon SE: Reversal of resistance to taxol and taxotere in a human myeloma cell line model of MDR1. Proc AACR 33:481, 1992.

53. Weinstein RS, Hansen KK, Macbeth RB, **Dalton WS**. Expression of the *mdr1* gene (P-glycoprotein) in breast cancer, 1992.
54. Nemunaitis J, Ash R, Freedman M, **Dalton W**, Deeg J, Elfenbein G, Rifkin R, Shadduck R, Rubin A, Agosti J: Phase III double blind trial of rhGM-CSF following allogeneic bone marrow transplant (BMT). ASH 34th Annual Meeting, Nov, 1992.
55. Glasser L, Fiederlein RL, **Dalton WS**, Vogler WR. The effect of alkyl-lysophospholipids (ALP) on human myeloma cell lines. ASH 34th Annual Meeting, Nov, 1992.
56. Salmon SE, Miller TP, List AF, Grogan TM, **Dalton WS**: Reversal of multidrug resistance in hematologic malignancies with chemosensitizers: laboratory and clinical studies. 4th Int'l Congress on Anti-Cancer Chemotherapy, Paris, France, Feb, 1993.
57. **Dalton WS**, Miller TP, and Grogan TM: Multidrug-resistance in lymphomas. Journal of Cellular Biochemistry, Keystone Symposia on Molecular & Cellular Biology, Supp 17E:257, March 29-April 25, 1993.
58. **Dalton WS**, Grogan TM, Miller TP, List AF and Salmon SE: Modulation of multidrug resistance in the laboratory and the clinic. General Motors Cancer Research Foundation International Symposium, Toronto Canada, May 1993.
59. Klimecki WT, Futscher BW, Grogan TM, and **Dalton WS**: P-glycoprotein is expressed in normal circulating granulocytes without measurable function. Proc 84th AACR, 34:23, May, 1993.
60. **Dalton WS**, Gleason-Guzman MC, Foley NE: Mitoxantrone selects for non-P-glycoprotein resistance in a human myeloma cell line. Proc 84th AACR, 34:305, May, 1993.
61. Abbaszadegan MR, Futscher BW, and **Dalton WS**: Evaluation of verapamil resistance in a multi-drug resistant myeloma cell line. Proc 84th AACR, 34:324, May, 1993.
62. Dorr RT, Liddil JD, **Dalton WS**, Galler L, and Hersh EM: The cyanoaziridine imexon (I) produces protein-linked DNA single strand breaks (SSB) possibly to topoisomerase I inhibition. Proc 84th AACR, 34:328, May, 1993.
63. Hersh EM, Edwards WR, Taylor CW, Dorr RT, Taetle R, **Dalton WS**, and Salmon SE: In-vitro and in-vivo antitumor activity of the cyanoaziridine compound imexon. Proc 84th AACR, 34:374, May, 1993.
64. Futscher BW, Campbell K, and **Dalton WS**: Chronic verapamil exposure can cause hypersensitivity to nitrosoureas. Proc 84th AACR, 34:498, May, 1993.
65. Modiano MR, Peng YM, Xu MJ, Baier M, Booth A, Villar H, Lippman S, Villar-Werstler P, and **Dalton WS**: Chemoprevention of breast cancer with fenretinide (4-HPR): data from benign and malignant breast tissue and plasma 4-HPR kinetics. Proc 84th AACR, 34:552, May, 1993.
66. **Dalton WS**, Taylor C, Mosley K, Dorr R, Salmon S: Combination chemotherapy with cyclophosphamide (C), vincristine (V), adriamycin (A), dexamethasone (D) (CVAD) plus quinine (Q) and verapamil (VL) in patients with advanced breast cancer. Proc ASCO, 12:63, May 1993.
67. Bauman PA, **Dalton WS**, Cress AE: Cytokeratin and drug resistance. Proc AACR, May, 1993.
68. List AF, Grimm M, Glinsmann-Gibson B, Foley N, **Dalton W**: Relative cytotoxicity and P-glycoprotein binding avidity of idarubicin, daunorubicin and mitoxantrone in multidrug resistant (MDR) cell lines. Proc AACR, May, 1993.
69. **Dalton WS**. Drug resistance in cancer: laboratory and clinical studies. AACR Special Meeting, Molecular Biology in Clinical Oncology: A Workshop, Aspen, CO, July 1993.
70. Taylor CW, List AF, Azar CA, Rifkin RM, Mosley K, **Dalton WS**. High dose mitoxantrone (M), thiotepa (T) and

cyclophosphamide (C) plus autologous stem cell rescue (ASCR) in patients with breast cancer. 16th Annual San Antonio Breast Cancer Symposium, slide #211, November 5-6, 1993.

71. Nemunaitis J, Rosenfeld C, Ash R, Flomenberg N, Friedman M, Deeg J, Appelbaum F, Singer JW, **Dalton W**, Effenbein G, Rifkin R, Rubin A, Agosti J, Hayes FA, Shadduck RK. Phase III double-blind trial of rhGM-CSF (sargramostim) following allogeneic bone marrow transplant (BMT). ASH, Dec 1993.
72. List AF, Spier CS, Abbaszadegan M, Grogan TM, Greer JP, Wolff SN, Scheper RJ, **Dalton WS**. Non-P-glycoprotein (PGP) mediated multidrug resistance (MDR): Identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia (AML). ASH, Dec 1993.
73. Salmon SE, Miller TP, Grogan T, List A, and **Dalton WS**. Reversal of multidrug resistance (MDR) with chemosensitizers: An emerging clinical reality. ICN-UCLA Symposium on Molecular Basis of Cancer Therapy, Tamarron, Colorado, March 1994.
74. List AF, **Dalton WS**. Mechanisms of multidrug resistance (MDR) in acute myeloid leukemia (AML). International Symposium: Acute Leukemias V, Experimental Approaches and Management of Refractory Disease, Münster, Federal Republic of Germany, February 27 - March 2, 1994.
75. Edwards WR, Miesfeld RL and **Dalton WS**. Level of Bcl-2 expression corresponds to level of drug resistance in WEHI 7.2 transfected cells. Proc AACR, 35:206, March 1994.
76. Klimecki WT, Taylor CW, **Dalton WS**. Inhibition of natural killer cell function by multi-drug resistance chemosensitizers does not correlate with inhibition of P-glycoprotein mediated efflux. Proc AACR, 35:493, March 1994.
77. Gleason-Guzman M, Harding MW, **Dalton WS**. Analysis of novel FKBP12 ligands as modulators of multidrug resistance. Proc AACR, 35:359, March 1994.
78. Abbaszadegan MR, Futscher BW, Domann F, List A, **Dalton WS**. Analysis of MRP expression in drug resistant cell lines and clinical specimens. Proc AACR, 35:207, March 1994.
79. Vogler WR, Geller RB, Winton EF, Heffner LT, Seay TE, Wingard JR, Holland HK, Hillyer CD, Saral R, McCollum J, Pecora A, Miller K, Lazarus H, Glasser L, **Dalton W**, Berdel WE, Beveridge RA. A phase II trial of edelfosine purging for autologous transplants in leukemia and myeloma. ASCO Annual Meeting, Dallas, TX, May 14-17, 1994.
80. Vogler WR, Berdel WE, **Dalton WS**, Miller KB, Lazarus HM, Brochstein JA, Geller RB, Beveridge RA. Autologous bone marrow transplant (ABMT) in acute leukemia using marrow purged with edelfosine (ET-18-OCH₃). International Society of Experimental Hematol, Minn, Minn, August 1994.
81. Bellamy W, Odeleye A, Finley P, Huizenga B, **Dalton W**, Weinstein R, Grogan T. An *in vivo* model of chemosensitization of multidrug resistant human myeloma cell line in SCID mice. Anti-Cancer Drugs, 5(Sup1):16, 1994.
82. Wissel PS, Brouwer K, Taylor C, **Dalton W**. GF120918 (GG918) tissue distribution in tumor bearing mice, favorable tumor retention of a potent P-glycoprotein blocker. Anti-Cancer Drugs, 5(Sup1):21, 1994.
83. **Dalton WS**. What have we learned from clinical MDR reversal studies? Anti-Cancer Drugs, 5(Sup1):69, 1994.
84. Taylor CW, Rifkin RM, List AF, González-Osete G, Dorr RT, Johnson CS, Roe, DJ, Mosley KE, **Dalton WS**. High dose mitoxantrone (M), Thiotepa (T) and cyclophosphamide (C) plus cyclosporin-A (CSA) followed by autologous stem cell rescue (ASCR) in patients with metastatic breast cancer (MBC). 17th Annual San Antonio Breast Cancer Symposium, November 1994.
85. Collins R, Wolff S, List A, Christiansen N, Piñairo L, Greer J, Goodman S, **Dalton W**, González G, Herzig G, Phillips G, Fay J. Prospective multicenter trial of donor buffy coat infusion for relapsed hematologic malignancy post-allogeneic bone marrow transplantation (BMT). ASH, Dec 1994.

86. Taetle R, Emerson J, Trent J, Thompson F, Weinstein R, Leong S, **Dalton W**, Emerson S, Alberts D. Overview of results obtained in the Cytogenetics Oncology Program Project (COPP). 6th International Workshop on Chromosomes in Solid Tumors, Feb 1995.
87. Campbell K, Futscher BW, Grogan TM, **Dalton WS**. Frequency of p53 mutations in multiple myeloma and association with drug resistance. *Proc AACR*, 36:217, March 1995.
88. Abbaszadegan MR, Cress AE, Futscher BW, **Dalton WS**. Alterations in P-glycoprotein intracellular location associated with enhanced MDR and resistance to chemosensitizers. *Proc AACR*, 36:330, March 1995.
89. Witherspoon SM, Emerson DL, Kerr BM, **Dalton WS** and Wissel PS. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the MDR inhibitor GF120918. *Proc AACR*, 36:331, March 1995.
90. Futscher BW, Watts GS, Peng Y-M and **Dalton WS**. Selection of methylation-variant cells and its association with an altered tumor cell phenotype. *Proc AACR*, 36:371, March 1995.
91. Vogler WR, Berdel WE, Geller RB, Brockstein JA, Beveridge RA, **Dalton WS**, Miller KB, Lazarus HM. A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. *PAF*, September 1995.
92. Salmon SE, Grogan TM, List A and **Dalton WS**. Multidrug resistance (MDR) in cancer: Mechanisms and approaches for circumvention. Sixth International Congress on Anti-Cancer Treatment, Paris, February 1996.
93. Hazlehurst L, Gros P and **Dalton WS**. Chromosome mediated gene transfer of the Mitoxantrone selected drug resistant phenotype. *AACR*, April 1996.
94. Skog PD, Foley NE, Gleason-Guzman MC, Hazlehurst LA, **Dalton WS**. Reversal of drug resistance in multiple myeloma with Lazaroid compound U-74389. *AACR*, April 1996.
95. Gleason-Guzman MC, Foley NE, Jones SA and **Dalton WS**. Activity of Camptothecin analogue (SN-38) in drug resistant human myeloma cell lines. *AACR*, April 1996.
96. Futscher BW and **Dalton WS**. Activation of *mdr1* gene expression is associated with cytosine methylation of its CpG island. *AACR*, April 1996.
97. List A, Spier C, Karanes C, Greer J, Moore J, Weinberger B, Grogan T, **Dalton W**, Litchman M, Pearce T. Phase I study of SDZ PSC-833 as a modulator of daunomycin resistance in acute leukemia. *AACR*, April 1996.
98. Vogler WR, Berdel WE, Winton EF, Gordon DS, Geller RB, Heffner LT, Brochstein JA, Beveridge RA, **Dalton WS**, Miller KB, Lazarus HM. A phase I/II trial of edelfosine purging for autologous bone marrow transplantation (ABMT) in acute leukemia. *ASCO*, May 1996.
99. Rimsza L, **Dalton W**, Campbell K, Salmon S, Grogan T. The non-Pgp multidrug resistance protein LRP56, the major vault nucleocytoplasmic transport molecule is frequently expressed in Multiple Myeloma. IV International Workshop on Multiple Myeloma, June, 1997.
100. Landowski TH, Guzman MG, **Dalton WS**. Differential sensitivity to Fas mediated apoptosis in drug resistant cell lines. *Blood* 88:253, 1996.
101. **Dalton W**, Greipp P, Greenberg P, Stiff P, et al. Phase I study of the chemosensitizers SDZ PSC 833 in combination with VAD chemotherapy to reverse multidrug resistance. *Blood* 88:2638, 1996.
102. List AF, Karanes C, Dorr R, Spier C, Grogan T, Greer J, Moore J, Weinberger J, Schiller G, **Dalton W**, Pearce T, Litchman M. Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC-833: Results of a phase I/II multicenter study. *Blood* 88:1156, 1996.

103. Catlett R, Garcia R, Fujita D, Moscinski L, Ballester O, **Dalton W**, and Jove R. Constitutive activation of STAT signaling occurs with high frequency in human breast carcinoma and multiple myeloma cells. Thirteenth Annual Meeting on Oncogenes, Frederick, MD, June 18-21, 1997.
104. Schreiber R, Coppola D, Mora L, **Dalton W**, Karl R. Modifications in Fas and RB protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Society of Surgical Oncology (submitted), 1997.
105. Vora J, **Dalton W**, Whitfield L, Grove W, Chetan L. Pharmacokinetics of CI-958 with cyclosporine in patients with advanced myeloma. Amer Assn of Pharmaceutical Scientists, Nov 1997.
106. Oshiro M, Landowski TH, **Dalton WS**. Influence of Interleukin-6 response to Fas and chemotherapeutic drug induced apoptosis in myeloma cell lines. ASH, 90:10:2203, December 1997.
107. Damiano J, Cress AE, **Dalton WS**. Upregulation of integrin VLA-4 is associated with low level drug resistance in human myeloma cells. ASH, 90:10:2206, December 1997.
108. Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Kogut N, Taranfuo S, Stiff P, Pinero L, **Dalton WS**, et al. A phase III study evaluation CD34+ - selected versus unselected autologous peripheral blood progenitor cell transplantation for patients with advanced multiple myeloma: engraftment results. ASH, 90:10:960, December 1997.
109. Vescio, R, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer N, Kogut S, Taranfuo S, Stiff P, Pinero L, **Dalton WS**, et al. Increase in circulating tumor cell burden during mobilization chemotherapy predicts for relapse after autologous transplantation in multiple myeloma patients. ASH, 90:10:2515, December 1997.
110. Vescio, R, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer N, Kogut S, Taranfuo S, Stiff P, Pinero L, **Dalton WS**, et al. Myeloma cell tumor reduction in PBPC autografts following CD34 selection: the results of a phase III trial using the ceprate device. ASH, 90:10:1872, December 1997.
111. Vescio, R, Wu C, Rettig M, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer N, Kogut S, Taranfuo S, Stiff P, Pinero L, **Dalton WS**, et al. The detection of KSHV is increased by mobilization chemotherapy and reduced in autografts by CD34-selection. ASH, 90:10:2516, December 1997.
112. Vescio, R, Berenson J, Schiller G, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer N, Sahebi F, Taranfuo S, Stiff P, Pineiro L, **Dalton WS**, et al. Autologous peripheral blood progenitor cell (PBCB) transplantation for patients with advanced multiple myeloma: results of a phase III study evaluating CD34- selected versus unselected autografts. Fifth International Blood Cell Transplantation Symposium, 1997.
113. Landowski TH, Oshiro MM, **Dalton WS**. Cytotoxic activity of chemotherapeutic drugs does not require Fas receptor/ligand interactions. Proc AACR, 39:1211, March 1998.
114. Landowski TH, Qu N, Buyuksal I, Painter JS, **Dalton WS**. Mutations in the Fas antigen of multiple myeloma patients. Proc AACR, 39:3141, March 1998.
115. Hazlehurst LA, **Dalton WS**. Dexamethasone induced nuclear translocation of the glucocorticoid receptor coincides with increased sensitivity to dexamethasone in a multidrug resistant human myeloma cell line. Proc AACR, 39:3266, March 1998.
116. Catlett-Falcone R, Landowski T, Oshiro M, Moscinski L, **Dalton W**, Jove R. Activation of STAT signaling pathways associated with oncogenesis in human multiple myeloma cells. Proc AACR, 39:3171, March 1998.
117. Catlett-Falcone R, Landowski T, Oshiro M, Turkson J, **Dalton W**, Jove R. Elevated IL-6 dependent Stat3 signaling human multiple myeloma tumor cells confers resistance to apoptosis. Tyrosine Phosphorylation and Cell Signaling Meeting, Oncogene, August 1998.
118. Ross D, Doyle L, Hazlehurst L, Yang W, Greenberger L, Hacker M, Abruzzo L, **Dalton W**. Mitoxantrone-resistant

- human 8226 myeloma cells overexpress breast cancer resistance protein (BCRP). *ASH*, 92:10:2785, December 1998.
119. Oshiro MM, Landowski TH, Catlett-Falcone R, Jove R, **Dalton WS**. Stat3-mediated induction of Bcl-XI by interleukin-6 confers resistance to apoptosis in human myeloma tumor cells. *ASH*, 92:10:2803, December 1998.
 120. Case Jr. DC, Jain V, Stiff P, Jansen J, Stewart AK, Shurafa M, Hussein M, Heffner LT, Irwin D, Greipp P, **Dalton W**, Fienberg W, Gucaip R, Anderson K, Catlett J, Lake D, Pincus S, Kerr R, Shustik C, Archinal-Mattheis A, Tarassoff P, Litchman M. Phase II Study of PSC 833 (PSC) and VAD Chemotherapy in patients with VAD-refractory multiple myeloma (MM). *ASH*, 92:10:427, December 1998.
 121. Catlett-Falcone R, Landowski TH, Oshiro MM, Nunez G, **Dalton WS**, Jove R. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human myeloma cells. *Proc AACR* 40:3955, April 1999.
 122. Oshiro MM, Landowski TH, Catlett-Falcone R, Nunez G, Jove R, **Dalton WS**. STAT3-mediated regulation of Bcl-xl expression in U266 myeloma cells confers resistance to Fas and chemotherapy drug induced apoptosis. *Proc AACR* 40:4869, April 1999.
 123. Bolick SCE, Campbell K, Hamilton A, Sebt SM, **Dalton WS**. Myeloma cells with activated N-Ras are sensitive to FTI-277. *Proc AACR* 40:832, April 1999.
 124. Hazlehurst LA, Wisner L, **Dalton WS**. Activation of $\beta 1$ integrin induces intrinsic drug resistance in the myeloma 8226 cell line: correlation with decreased proliferative index and increased p27 levels. *Proc AACR* 40: 2149, April 1999.
 125. Damiano JS, **Dalton WS**. Ligation of the integrins VLA-4 and VLA-5 by soluble fibronectin suppresses drug-induced apoptosis in leukemic K562 cells. *Proc AACR* 40:2148, April 1999.
 126. Ross DD, Yang W, Abruzzo LV, **Dalton WS**, Schneider E, Lage H, Deitel M, Greenberger L, Cole SPC, Doyle LA. Breast Cancer Resistance Protein (BCRP) mRNA is overexpressed in atypical multidrug-resistant human cancer cell lines selected with mitoxantrone. *Proc AACR* 40:2092, April 1999.
 127. Einstein Jr. A, Lush, R, Rago R, Ko Y-j, Bubley G, Henner WD, Beer T, Chatta G, Shepard R, Unger P, Merica EA, Ette E, Harding MW, **Dalton WS**. A Phase II study of safety, pharmacokinetics and efficacy of Incel (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in advanced hormone refractory prostate cancer (HRPC). European Cancer Conference, September 1999, Vienna, Austria.
 128. Catlett-Falcone R, Landowski T, Oshiro M, Turkson J, Levitzki A, Nunez G, **Dalton WS**, Jove R. Constitutive activation of STAT3 signaling in human myeloma tumor cells contributes to malignant progression by preventing apoptosis. OncoGene Meeting, June 1999, Frederick, MD.
 129. **Dalton WS**, Landowski T, Jove R. Fas/Fas ligand: the role of death receptors in myeloma tumorigenesis and progression. VII International Multiple Myeloma Workshop, September 1999, Stockholm, Sweden.
 130. **Dalton WS**, Jove R, Yu H. Molecular determinants of treatment response in myeloma. Second Experts' Roundtable on Immunotherapy for Multiple Myeloma, September 1999, Stockholm, Sweden.
 131. Rosen S, Gandhi V, Ayres M, Halgren R, Pillay S, **Dalton WS**, Krett N. 8-Chloro-Adenosine is a potential therapeutic agent for multiple myeloma, September 1999.
 132. Sullivan D, Rago R, Garland L, Dellaportas AM, Mahany JJ, Lush RM, Skillings J, Bulanagui C, **Dalton WS**. A Phase I study of BMS-188797, a new taxane analogue, Molecular Targets & Cancer Therapeutics: Discovery, Development, & Clinical Validation, NCI EORTC Drug Discovery, November 1999, Washington, D.C.
 133. **Dalton WS**, Hazlehurst L, Damiano J, Shtil A. Cell adhesion mediated drug resistance (CAM-DR): a new molecular target for drug discovery, Molecular Targets & Cancer Therapeutics: Discovery, Development, & Clinical Validation, NCI EORTC Drug Discovery, November 1999, Washington, D.C.

134. Sullivan DM, Partyka JS, Fields KK, Goldstein SC, Field TL, Djulbegovic B, Perkins JB, McIsaac CE, Lush RM, **Dalton WS**. A phase I study of intensive-dose melphalan, topotecan, and VP-16 phosphate (MTV) followed by autologous stem cell rescue in patients with multiple myeloma, *Molecular Targets & Cancer Therapeutics: Discovery, Development, & Clinical Validation*, NCI EORTC Drug Discovery, November 1999, Washington, D.C.
135. Einstein A, Lush R, Rago R, Ko YJ, Bublely G, Henner WD, Beer T, Chatta G, Shepard R, Unger P, Merica EA, Ette E, Harding MW, **Dalton WS**. A phase II study of the safety, pharmacokinetics, and efficacy of Incel™ (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in hormone refractory prostate cancer (HRPC). *Molecular Targets & Cancer Therapeutics: Discovery, Development, & Clinical Validation*, NCI EORTC Drug Discovery, November 1999, Washington, D.C.
136. Shtil A, Padyukova N, Karpeisky M, **Dalton WS**. Novel bisphosphonate-based compounds for circumventing drug resistance in the bone-targeting human tumor cells. *AACR Annual Meeting*, April 2000, San Francisco, CA.
137. Oshiro M, Landowski T, Jove R, **Dalton WS**. Inhibition of the IL-6/Jak/Stat pathway and its effects on drug induced apoptosis. *AACR Annual Meeting*, April 2000, San Francisco, CA.
138. Landowski T, Buyuksal I, Moscinski L, Goldstein S, **Dalton WS**. CD95 death receptor mutations in Non-Hodgkin's lymphoma. *AACR Annual Meeting*, April 2000, San Francisco, CA.
139. Catlett-Falcone R, Huang M, Burdelya L, Landowski T, Oshiro M, Moscinski L, Sullivan D, Yu H, **Dalton WS**, Jove R. Constitutive activation of STAT signaling in myeloid leukemia cells is associated with resistance to apoptosis. *AACR Annual Meeting*, April 2000, San Francisco, CA.
140. Scheffer G, Maliepaard M, Pijnenborg A, van Gastelen M, de Jong M, Schroeijers A, van der Valk P, Schinkel A, **Dalton WS**, Schellens J, Scheper RJ. Specific detection of breast cancer resistance protein with a monoclonal antibody. *AACR Annual Meeting*, April 2000, San Francisco, CA.
141. Garcia R, Sun G, Bowman T, Minton S, Muro-Cacho C, Ku N, Cox C, Falcone R, Parsons S, Kraker A, Levitzki A, **Dalton WS**, Sebti S, Jove R. Constitutive activation of STAT3 signaling by SRC and JAK tyrosine kinases regulates growth of human breast carcinoma cells. *AACR Annual Meeting*, April 2000, San Francisco, CA.
142. Hazlehurst LA, Buyuksal I, Loughrin T, **Dalton WS**. Adhesion of 8226 cells to fibronectin via $\beta 1$ integrins upregulates p27 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). *ISEH 29th Annual Meeting*, Tampa, FL, July 2000.
143. Shain K, Loughran T, **Dalton WS**. $\beta 1$ mediated adhesion to fibronectin protects cells from CD95 mediated apoptosis. *ISEH 29th Annual Meeting*, Tampa, FL, July 2000.
144. Sullivan D, **Dalton WS**, Djulbegovic B, Fields K, Field T, Goldstein S, Partyka J, Perkins J, Janssen W, Lush R, Gump J, Valkov N, McIsaac C. A phase I/II study of high-dose melphalan + topotecan +VP-16 phosphate (MTV) followed by autologous stem cell rescue in multiple myeloma. *ISEH 29th Annual Meeting*, Tampa, FL, July 2000.
145. Seiden M, Matulonis U, Swenerton K, Bramwell V, Harding M, Ette E, Seidman A, Toppmeyer D, Rago R, **Dalton WS**, Morris D, Rose P, Demetri G. Clinical trial results with Incel (biricodar dicitrate, VX-710) a dual inhibitor of P-glycoprotein (P-gp) and multi-drug resistance-associated protein (MRP1). *European Spring Oncology Conference*, Marbella, Spain, April, 2000.
146. Burdelya L, Niu G, Coppola D, Wei S, Djeu J, Landowski T, **Dalton WS**, Pardoll D, Yu H. Stat3-targeted gene therapy leads to production of soluble factors that activate macrophages. Immune component in Stat3 targeted gene therapy in murine B16 melanoma model: the role of macrophages. *AACR Conference*, San Francisco, CA, April, 2000.
147. Huang M, Catlett-Falcone R, Burdelya L, Landowski T, Oshiro M, Moscinski L, Loughran T, Sullivan D, Yu H, **Dalton WS**, Jove R. Constitutive activation of stat signaling in myeloid leukemia cells is associate with resistance to apoptosis.

148. Sullivan DM, Rago R, Ruckdeschel J, Dellaportas A, Mahany JJ, Lush R, **Dalton WS**, Bulanhagui C, Gupta E, Tarby C, Sonnichsen D, Gustafson N, Galland G. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, given every three weeks in patients with advanced malignancies.
149. **Dalton WS**, Hazlehurst L, Shain K, Damiano J. Signal transduction events associated with integrin signaling in myeloma cells. Expert's Roundtable on Angiogenesis, Boston, Mass, October, 2000.
150. Hazlehurst L, Wisner L, Storey J, Valkov N, Sullivan D, **Dalton WS**. Fibronectin adhesion via $\beta 1$ integrins confers resistance to topoisomerase II inhibitors by decreasing initial DNA damage secondary to altered topo II β activity and nuclear binding. AACR 92nd Annual Meeting, New Orleans, LA, March, 2001.
151. Shain K, Landowski T, Damiano J, **Dalton WS**. Fibronectin-mediated resistance to CD95-induced apoptosis in hematopoietic tumor cell lines correlates with increased cFLIP_L expression. AACR 92nd Annual Meeting, New Orleans, LA, March, 2001.
152. **Dalton WS**, Shain KH, Landowski TH. Cellular adhesion to fibronectin via $\beta 1$ integrins increases c-FLIP_L and inhibits CD95/Fas-mediated apoptosis: a novel mechanism of immune evasion. MMRF Cell Signaling Roundtable, Banff, Alberta, Canada, May 2001.
153. **Dalton WS**, Damiano J, Landowski TH, Hazlehurst L, Shain KH, Jove R. The tumor microenvironment: How it influences drug response and drug resistance in myeloma. 8th International Myeloma Workshop, Banff, Alberta, Canada, May, 2001.
154. Landowski TH, Oshiro M, Catlett-Falcone R, Jove R, **Dalton WS**. Inhibition of the JAK/STAT pathway enhances Fas-mediated apoptosis but reduces cytotoxic drug activity in U266 myeloma cells. 8th International Myeloma Workshop, Banff, Alberta, Canada, May, 2001.
155. **Dalton WS**, Shain K, Hazlehurst L. The influence of the microenvironment on drug response and drug resistance in multiple myeloma. International Symposium: Recent Advances in the Management of Multiple Myeloma, Heidelberg, Germany, Aug-Sep, 2001.
156. Hazlehurst L, Painter J, **Dalton WS**. Fibronectin adhesion via $\beta 1$ integrins confers resistance to topoisomerase (topo) II inhibitors by decreasing initial DNA damage secondary to altered topo II β nuclear binding and increased association with HDAC1. AACR-NCI-EORTC International Conference: Molecular Targets & Cancer Therapeutics: Discovery, Biology, & Clinical Applications, Oct-Nov, 2001.
157. Landowski T, **Dalton WS**. Inhibition of NF-KB activation by proteasome inhibitors reverses the CAM-DR phenotype in myeloma cells and enhances the cytotoxic activity of chemotherapeutic drugs. AACR-NCI-EORTC International Conference: Molecular Targets & Cancer Therapeutics: Discovery, Biology, & Clinical Applications, Oct-Nov, 2001.
158. Bolick S, Sebt S, Landowski T, **Dalton WS**. Activity of farnesyl transferase inhibitor, FTI-277, in human myeloma cells correlates with inhibition of Ras processing. AACR-NCI-EORTC International Conference: Molecular Targets & Cancer Therapeutics: Discovery, Biology, & Clinical Applications, Oct-Nov, 2001.
159. Shain K, Landowski T, **Dalton WS**. Cellular adhesion inhibits CD95/Fas-mediated apoptosis by altering the intracellular localization and availability of c-FLIP_L. ASH 43rd Annual Meeting, December, 2001.
160. **Dalton WS**. Drug Resistance and drug development in multiple myeloma. ASH 43rd Annual Meeting, December, 2001.
161. Landowski T, **Dalton WS**. Myeloma cell adhesion to fibronectin activates NF-kappaB and induces the expression of genes contributing to cell adhesion mediated drug resistance. ASH 43rd Annual Meeting, December, 2001.
162. Painter J, Hazlehurst L, Shain K, Saporta S, Boulware D, **Dalton WS**. De novo drug resistance associated with cell adhesion protects myeloma cells from melphalan induced cytotoxicity: comparison of de novo and acquired mechanisms of melphalan resistance in myeloma cells. ASH 43rd Annual Meeting, December, 2001.

163. Nefedova J, **Dalton WS**. Myeloma cells and the microenvironment: role of bone marrow stromal cells in protection of myeloma cells from drug-induced apoptosis. ASH 43rd Annual Meeting, December, 2001.
164. Moscinski L, Mora L, Eweis I, Hill B, **Dalton WS**, Jove R. Activation of stat3 and down-regulation of p27 are associated with the neoplastic phenotype in multiple myeloma. ASH 44th Annual Meeting, December, 2002.
165. Hazelhurst L, Painter J, Shain K, Saporta S, **Dalton WS**. Cell adhesion mediated melphalan resistance is mechanistically distinct from acquired melphalan resistance and does not correlate with melphalan induced crosslinks. ASH 44th Annual Meeting, December, 2002.

TEACHING:

1. James Liddil, Master's Degree, Toxicology (1987), "Mechanism of the cytotoxic actions of tumor necrosis factor in cultured cancer cells." Research Specialist, University of Arizona
2. William Bellamy, Ph.D. Degree, Pharmacology/Toxicology (1988), "Mechanisms of doxorubicin resistance in MDR human myeloma cells." Assistant Professor, University of Arizona
3. Nancy Shipp, Ph.D. Degree, Pharmacology/Toxicology (1990), "Characterization of mitoxantrone cardiotoxicity in cultured heart cells." Research Scientist FGN, Inc.
4. Pamela Parrish, Master's Degree, Pharmacology (1990)--Primary Advisor, "Decreased intracellular mitoxantrone in resistant MCF-7 breast cancer cells is attributed to an energy dependent efflux." Research Specialist, Veterans Administration Medical Center, Tucson
5. Patricia Bauman, Ph.D., Pharmacology (1993)--"Interactions of mitoxantrone with cytokeratin in human and murine tumor cells." Post-Doctoral Fellow, Department of Oncology, Vanderbilt University.
6. Walter Klimecki, Ph.D., Pharmacology (1994)--Primary Advisor, "Characterization of P-glycoprotein in normal peripheral leukocytes." Post-Doctoral Fellow, Departments of Pharmacology and Toxicology, University of Arizona.
7. Mohammad Abbaszadegan, Ph.D. Pharmacology (1995) --Primary Advisor, "Evaluation of verapamil resistance in multidrug resistant myeloma cell line." Post-Doctoral Fellow, National Institute of Genomic Research/NIH.
8. Wayne Edwards, M.S. Graduate Student, Cancer Biology (1995)--Primary Advisor, "Role of BCL-2 in drug-resistance." Graduated from Medical School, 1997.
9. Bernard Futscher, Ph.D., Postdoctoral Fellow, Pharmacology (1990-1993)--Primary Advisor. Associate Professor, Pharmacology, University of Arizona
10. Patrick Skog, Undergraduate, Honors Thesis Biochemistry Advisor (1994).
11. Shawn Cochran, Undergraduate, Honors Thesis Biochemistry Advisor (1994).
12. Lori Hazlehurst, Ph.D., Postdoctoral Fellow, Pharmacology (1994-1998)--Primary Advisor, Research Asst. Professor, Univ. of South Florida.
13. Terry Landowski, Ph.D., Postdoctoral Fellow, Pharmacology (1994-1999)--Primary Advisor, Research Asst. Professor, Univ. of South Florida.
14. Ning Qu, M.D., Ph.D., Postdoctoral Fellow, Pharmacology (1994-1996)--Primary Advisor, Post-Doctoral Fellow, Univ. of Arizona (Laboratory of Dr. Eugene Gerner).
15. Jason Damiano, Ph.D. Graduate Student, Pharmacology (1995-2000)--Primary Advisor. Research Associate, Burnham Inst. LaJolla, California (Laboratory of Dr. John Reed).
16. Marc Oshiro, Ph.D. Graduate Student, Pharmacology (1995-2000)--Primary Advisor. Post-Doctoral Fellow, Univ. of Arizona, Tucson, Az. (Laboratory of Dr. B. Futscher).
17. Ken Shain, Ph.D. Graduate Student, Biochemistry (1997-2001)--Primary Advisor. Post-Doctoral Fellow, Univ. of S. Florida. 2002-Medical Student, University of South Florida.
18. Alexander Shtil, Ph.D., Postdoctoral Fellow, Biochemistry (1997-1999)--Primary Advisor, Research Associate, Memorial Sloan-Kettering, NY, NY. (Laboratory of Dr. K. Scotto)
19. Jonathan Storey, Undergraduate Student, Biochemistry (1998-1999)--Primary Advisor. Medical Student, Univ. of S. Florida.
20. Debora Ghosh, Master's degree Graduate Student, Biochemistry (1998-2000)--Primary Advisor
21. Sophie Bolick, Ph.D. Graduate Student, Biochemistry (1998-2001)--Primary Advisor
22. Yulia Nefadova, M.D., Ph.D., Postdoctoral Fellow, Biochemistry (2000-present)--Primary Advisor.